10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 10-Q

____________________

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended September 30, 2018
	OR
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from  to

Commission File No.: 001-16753

AMN HEALTHCARE SERVICES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	06-1500476
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
12400 High Bluff Drive, Suite 100 San Diego, California	92130
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866) 871-8519

____________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x  No  o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  x No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer   x	Accelerated filer   o	Non-accelerated filer  o
Smaller reporting company o	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange

Act).  Yes   o  No  x

As of October 31, 2018, there were 46,867,877 shares of common stock, $0.01 par value, outstanding.

TABLE OF CONTENTS

Item		Page
	PART I - FINANCIAL INFORMATION
1.	Condensed Consolidated Financial Statements (unaudited):	1
	Condensed Consolidated Balance Sheets, As of September 30, 2018 and December 31, 2017	1
	Condensed Consolidated Statements of Comprehensive Income, For the Three and Nine Months Ended September 30, 2018 and 2017	2
	Condensed Consolidated Statements of Cash Flows, For the Nine Months Ended September 30, 2018 and 2017	3
	Notes to Unaudited Condensed Consolidated Financial Statements	5
2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
3.	Quantitative and Qualitative Disclosures about Market Risk	23
4.	Controls and Procedures	24
	PART II - OTHER INFORMATION
1.	Legal Proceedings	25
1A.	Risk Factors	25
2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
3.	Defaults Upon Senior Securities	25
4.	Mine Safety Disclosures	25
5.	Other Information	25
6.	Exhibits	26
	Signatures	27

PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

AMN HEALTHCARE SERVICES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited and in thousands, except par value)

	September 30, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	18,614		$	15,147
Accounts receivable, net of allowances of $9,741 and $9,801 at September 30, 2018 and December 31, 2017, respectively	366,436			350,496
Accounts receivable, subcontractor	44,891			41,012
Prepaid expenses	14,540			16,505
Other current assets	35,358			50,993
Total current assets	479,839			474,153
Restricted cash, cash equivalents and investments	59,453			64,315
Fixed assets, net of accumulated depreciation of $109,846 and $97,889 at September 30, 2018 and December 31, 2017, respectively	86,817			73,431
Other assets	93,206			74,366
Goodwill	438,299			340,596
Intangible assets, net of accumulated amortization of $108,283 and $90,685 at September 30, 2018 and December 31, 2017, respectively	332,788			227,096
Total assets	$	1,490,402		$	1,253,957
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	142,543		$	130,319
Accrued compensation and benefits	135,632			121,423
Deferred revenue	13,107			8,384
Other current liabilities	11,806			5,146
Total current liabilities	303,088			265,272
Revolving credit facility	150,000			—
Notes payable, less unamortized fees	320,416			319,843
Deferred income taxes, net	24,651			27,036
Other long-term liabilities	77,527			79,279
Total liabilities	875,682			691,430
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 10,000 shares authorized; none issued and outstanding at September 30, 2018 and December 31, 2017	—			—
Common stock, $0.01 par value; 200,000 shares authorized; 48,809 issued and 46,914 outstanding at September 30, 2018 and 48,411 issued and 47,481 outstanding at December 31, 2017	488			484
Additional paid-in capital	449,868			453,351
Treasury stock, at cost (1,895 and 930 shares at September 30, 2018 and December 31, 2017, respectively)	(86,175		)	(33,425		)
Retained earnings	250,446			142,229
Accumulated other comprehensive income (loss)	93			(112		)
Total stockholders’ equity	614,720			562,527
Total liabilities and stockholders’ equity	$	1,490,402		$	1,253,957

See accompanying notes to unaudited condensed consolidated financial statements.

1

AMN HEALTHCARE SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited and in thousands, except per share amounts)

	Three Months Ended September 30,					Nine Months Ended September 30,
	2018		2017			2018		2017
Revenue	$	526,842	$	494,406		$	1,607,439	$	1,479,378
Cost of revenue	351,695		334,867			1,083,512		997,051
Gross profit	175,147		159,539			523,927		482,327
Operating expenses:
Selling, general and administrative	121,216		100,579			341,488		299,325
Depreciation and amortization	11,296		8,132			29,788		23,759
Total operating expenses	132,512		108,711			371,276		323,084
Income from operations	42,635		50,828			152,651		159,243
Interest expense, net, and other	4,649		4,837			16,360		14,895
Income before income taxes	37,986		45,991			136,291		144,348
Income tax expense	10,068		17,863			30,163		52,957
Net income	$	27,918	$	28,128		$	106,128	$	91,391
Other comprehensive income (loss):
Foreign currency translation and other	133		(73		)	205		(111		)
Cash flow hedge, net of income taxes	—		—			—		(15		)
Other comprehensive income (loss)	133		(73		)	205		(126		)
Comprehensive income	$	28,051	$	28,055		$	106,333	$	91,265
Net income per common share:
Basic	$	0.59	$	0.59		$	2.23	$	1.91
Diluted	$	0.58	$	0.57		$	2.17	$	1.85
Weighted average common shares outstanding:
Basic	47,286		47,912			47,556		47,870
Diluted	48,529		49,445			48,859		49,480

See accompanying notes to unaudited condensed consolidated financial statements.

2

AMN HEALTHCARE SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited and in thousands)

	Nine Months Ended September 30,
	2018			2017 *As Adjusted
Cash flows from operating activities:
Net income	$	106,128		$	91,391
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	29,788			23,759
Non-cash interest expense and other	591			1,718
Write-off of fees on the prior credit facilities	574			—
Change in fair value of contingent consideration	(1,307		)	66
Increase in allowances for doubtful accounts and sales credits	6,240			9,012
Provision for deferred income taxes	(2,384		)	(9,512		)
Share-based compensation	7,954			7,720
Loss on disposal or sale of fixed assets	40			130
Amortization of discount on investments	(78		)	(112		)
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable	743			(10,631		)
Accounts receivable, subcontractor	(3,879		)	12,033
Income taxes receivable	12,997			(1,854		)
Prepaid expenses	2,334			(1,643		)
Other current assets	446			6,100
Other assets	(1,019		)	(5,204		)
Accounts payable and accrued expenses	7,311			(20,442		)
Accrued compensation and benefits	11,014			3,991
Other liabilities	(10,423		)	(5,112		)
Deferred revenue	1,062			678
Restricted investments balance	(86		)	8
Net cash provided by operating activities	168,046			102,096
Cash flows from investing activities:
Purchase and development of fixed assets	(23,922		)	(17,168		)
Purchase of investments	(27,185		)	(11,021		)
Proceeds from maturity of investments	10,400			17,200
Payments to fund deferred compensation plan	(7,800		)	(10,056		)
Equity investment	(4,600		)	(2,000		)
Cash paid for acquisitions, net of cash received	(217,361		)	—
Cash paid for other intangibles	(1,180		)	—
Cash paid for working capital adjustments and holdback liability for prior year acquisitions	—			(1,000		)
Net cash used in investing activities	(271,648		)	(24,045		)

3

	Nine Months Ended September 30,
	2018			2017 *As Adjusted
Cash flows from financing activities:
Payments on term loans	—			(44,063		)
Payments on revolving credit facility	(45,000		)	—
Proceeds from revolving credit facility	195,000			—
Repurchase of common stock	(52,750		)	(7,097		)
Payment of financing costs	(2,331		)	—
Earn-out payments for prior acquisitions	(1,713		)	(3,677		)
Proceeds from termination of derivative contract	—			85
Cash paid for shares withheld for taxes	(11,432		)	(9,072		)
Net cash provided by (used in) financing activities	81,774			(63,824		)
Effect of exchange rate changes on cash	205			(111		)
Net increase (decrease) in cash, cash equivalents and restricted cash	(21,623		)	14,116
Cash, cash equivalents and restricted cash at beginning of period	98,894			51,028
Cash, cash equivalents and restricted cash at end of period	$	77,271		$	65,144
Supplemental disclosures of cash flow information:
Cash paid for interest (net of $368 and $113 capitalized for the nine months ended September 30, 2018 and 2017, respectively)	$	11,521		$	9,395
Cash paid for income taxes	$	21,223		$	65,998
Acquisitions:
Fair value of tangible assets acquired in acquisitions, net of cash received	$	24,027		$	—
Goodwill	97,703			—
Intangible assets	122,111			—
Liabilities assumed	(16,380		)	—
Earn-out liabilities	(10,100		)	—
Net cash paid for acquisitions	$	217,361		$	—
Supplemental disclosures of non-cash investing and financing activities:
Purchase of fixed assets recorded in accounts payable and accrued expenses	$	4,504		$	3,156

* See Note (1) for a summary of adjustments.

See accompanying notes to unaudited condensed consolidated financial statements.

4

AMN HEALTHCARE SERVICES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

1. BASIS OF PRESENTATION

The condensed consolidated balance sheets and related condensed consolidated statements of comprehensive income and cash flows contained in this Quarterly Report on Form 10-Q (this “Quarterly Report”), which are unaudited, include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The results of operations for the interim period are not necessarily indicative of the results to be expected for any other interim period or for the entire fiscal year or for any future period.

The unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). Please refer to the Company’s audited consolidated financial statements and the related notes for the fiscal year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on February 16, 2018 (“2017 Annual Report”).

The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. Actual results could differ from those estimates under different assumptions or conditions.

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606).” The FASB also issued a series of other ASUs, which update ASU 2014-09 (collectively, the “new revenue recognition standard”). This new standard replaces all previous U.S. GAAP guidance on this topic and eliminates all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company adopted this standard effective January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Revenue from substantially all of our contracts with customers continues to be recognized over time as services are rendered. The Company recognized the cumulative effect of adopting this guidance as an adjustment to its opening balance of retained earnings of $2,089, net of tax, primarily related to capitalization of contract costs. Prior period amounts are not retrospectively adjusted and continue to be reported in accordance with the accounting standards in effect for those periods. The impact of the adoption of the new standard was not material to the Company’s condensed consolidated financial statements for the three and nine months ended September 30, 2018. The Company expects the impact to be immaterial on an ongoing basis. See additional information regarding revenue recognition and disaggregated revenue in Note (3), “Revenue Recognition” and Note (5), “Segment Information,” respectively.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities.” The FASB also subsequently issued ASU 2018-03, which provides amendments to ASU 2016-01. These standards require equity investments, except those accounted for using the equity method of accounting, to be measured at fair value with changes in fair value recognized through net income. The new guidance also provides a measurement alternative for equity investments that do not have readily determinable fair values, which were previously accounted for under the cost method of accounting, to be recorded at cost, less impairment, adjusted for observable price changes from orderly transactions for identical or similar investments of the same issuer. For public entities, these standards are effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the standards prospectively effective January 1, 2018 and elected to use the measurement alternative. See additional information in Note (7), “Fair Value Measurement.”

5

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The standard provides guidance on how certain cash receipts and payments are presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods, and requires a retrospective approach. The Company adopted this standard effective January 1, 2018 and the adoption did not have a material effect on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash.” The standard requires that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents (collectively, “restricted cash”). Therefore, restricted cash should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new guidance is effective for interim and annual periods beginning after December 15, 2017. The Company adopted this standard retrospectively effective January 1, 2018 and included certain restricted cash amounts for the period ended September 30, 2017 within the accompanying condensed consolidated statements of cash flows. These adjustments had no effect on previously reported results of operations or retained earnings. The following table provides a summary of the adjustments from amounts previously reported.

	Nine Months Ended September 30, 2017
	As Previously Reported			Adjustments			As Adjusted
Cash flows from operating activities:
Changes in assets and liabilities:
Other current assets	10,155			(4,055		)	6,100
Restricted cash, cash equivalents and investments balance	(9,761		)	9,769			8
Net cash provided by operating activities	96,382			5,714			102,096
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance	601			(601		)	—
Net cash used in investing activities	(23,444		)	(601		)	(24,045		)
Net increase in cash, cash equivalents and restricted cash	$	9,003		$	5,113		$	14,116
Cash, cash equivalents and restricted cash at the beginning of period	10,622			40,406			51,028
Cash, cash equivalents and restricted cash at the end of period	$	19,625		$	45,519		$	65,144

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets and related notes to the amounts presented in the accompanying condensed consolidated statements of cash flows.

	September 30, 2018			December 31, 2017
Cash and cash equivalents	$	18,614		$	15,147
Restricted cash and cash equivalents (included in other current assets)	22,227			25,506
Restricted cash, cash equivalents and investments	59,453			64,315
Total cash, cash equivalents and restricted cash and investments	100,294			104,968
Less restricted investments	(23,023		)	(6,074		)
Total cash, cash equivalents and restricted cash	$	77,271		$	98,894

There were no other material impacts to the Company's consolidated financial statements as a result of adopting these updated standards.

Reclassification

To conform to the current year presentation, certain reclassifications that are not material have been made to the prior year's balances in Note (10), “Balance Sheet Details."

6

2. ACQUISITIONS

As set forth below, the Company completed two acquisitions during the nine months ended September 30, 2018. The Company accounted for each acquisition using the acquisition method of accounting. Accordingly, it recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For each acquisition, the Company did not incur any material acquisition-related costs.

MedPartners Acquisition

On April 9, 2018, the Company completed its acquisition of MedPartners HIM (“MedPartners”), which provides case management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. The initial purchase price of $200,711 included (1) $196,533 cash consideration paid upon acquisition, funded through borrowings under the Company’s $400,000 secured revolving credit facility (the “Senior Credit Facility”), provided for under a credit agreement (the “New Credit Agreement”), dated as of February 9, 2018, by and among the Company and several lenders, and (2) a contingent earn-out payment of up to $20,000 with an estimated fair value of $4,400 as of the acquisition date. The contingent earn-out payment is based on (A) up to $10,000 based on the operating results of MedPartners for the twelve months ending December 31, 2018, and (B) up to $10,000 based on the operating results of MedPartners for the six months ending June 30, 2019. As the acquisition’s operations are not considered material, pro forma information is not provided. The results of MedPartners have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2018, $222 was returned to the Company for the final working capital settlement.

The preliminary allocation of the $200,711 purchase price consisted of (1) $28,425 of fair value of tangible assets acquired, which included $8,403 cash received, (2) $11,809 of liabilities assumed, (3) $103,000 of identified intangible assets, and (4) $81,095 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets includes $46,000 of trademarks and $57,000 of customer relationships with a weighted average useful life of approximately sixteen years.

Phillips DiPisa and Leaders For Today Acquisition

On April 6, 2018, the Company completed its acquisition of two related entities, Phillips DiPisa and Leaders For Today (“PDA and LFT”), which offer a range of leadership staffing and permanent placement solutions for the healthcare industry. The initial purchase price of $35,503 included (1) $30,268 cash consideration paid upon acquisition, funded through cash on hand, and (2) a contingent earn-out payment of up to $7,000 with an estimated fair value of $5,700 as of the acquisition date. The contingent earn-out payment is based on the operating results of PDA and LFT for the twelve months ending December 31, 2018. As the acquisition’s operations are not considered material, pro forma information is not provided. The results of PDA and LFT have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2018, $465 was returned to the Company for the final working capital settlement.

The preliminary allocation of the $35,503 purchase price consisted of (1) $4,356 of fair value of tangible assets acquired, which included $351 cash received, (2) $4,571 of liabilities assumed, (3) $19,110 of identified intangible assets, and (4) $16,608 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets includes $5,400 of trademarks, $8,000 of customer relationships and $5,710 of staffing databases with a weighted average useful life of approximately twelve years.

3. REVENUE RECOGNITION

Revenue primarily consists of fees earned from the temporary and permanent placement of healthcare professionals and executives as well as from the Company’s SaaS-based technology, including its vendor management systems and its scheduling software. Revenue is recognized when control of these services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Revenue from temporary staffing services is recognized as the services are rendered by clinical and non-clinical healthcare professionals. Under the Company’s managed services program arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own network of healthcare professionals along with those of third-party subcontractors. Revenue and the related direct costs under MSP arrangements are recorded in accordance with the accounting guidance on reporting revenue gross as a principal versus net as an agent. When the Company uses subcontractors and acts as an agent, revenue is recorded net of the related subcontractor’s expense. Revenue from executive search, physician permanent placement, and recruitment process outsourcing services is recognized as the services are rendered. The Company’s SaaS-based revenue is recognized ratably over the applicable arrangement’s service period.

7

The Company’s customers are primarily billed as services are rendered. Any fees billed in advance of being earned are recorded as deferred revenue. During the nine months ended September 30, 2018, the amount recognized as revenue that was previously deferred was not material.

Under the new revenue recognition standard, the Company has elected to apply the following practical expedients and optional exemptions:

• Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within selling, general and administrative expenses.

• Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date.

• Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.

See additional information regarding adoption of the new revenue standard in Note (1), “Basis of Presentation” and additional disclosures required by the new revenue standard in Note (5), “Segment Information.”

4. NET INCOME PER COMMON SHARE

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period. The following table sets forth the computation of basic and diluted net income per common share for the three and nine months ended September 30, 2018 and 2017, respectively:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Net income	$	27,918	$	28,128	$	106,128	$	91,391
Net income per common share - basic	$	0.59	$	0.59	$	2.23	$	1.91
Net income per common share - diluted	$	0.58	$	0.57	$	2.17	$	1.85
Weighted average common shares outstanding - basic	47,286		47,912		47,556		47,870
Plus dilutive effect of potential common shares	1,243		1,533		1,303		1,610
Weighted average common shares outstanding - diluted	48,529		49,445		48,859		49,480

Share-based awards to purchase 36 and 27 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2018, respectively, because the effect of these instruments was anti-dilutive. Share-based awards to purchase 10 and 14 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2017, respectively, because the effect of these instruments was anti-dilutive.

5. SEGMENT INFORMATION

The Company has three reportable segments: nurse and allied solutions, locum tenens solutions, and other workforce solutions.

The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes:

8

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Revenue
Nurse and allied solutions	$	306,292	$	302,933	$	977,199	$	917,183
Locum tenens solutions	101,102		111,415		311,516		322,473
Other workforce solutions	119,448		80,058		318,724		239,722
	$	526,842	$	494,406	$	1,607,439	$	1,479,378
Segment operating income
Nurse and allied solutions	$	42,165	$	40,807	$	137,906	$	134,638
Locum tenens solutions	10,992		14,438		34,321		39,028
Other workforce solutions	29,010		19,890		77,437		61,788
	82,167		75,135		249,664		235,454
Unallocated corporate overhead	26,427		13,698		59,271		44,732
Depreciation and amortization	11,296		8,132		29,788		23,759
Share-based compensation	1,809		2,477		7,954		7,720
Interest expense, net, and other	4,649		4,837		16,360		14,895
Income before income taxes	$	37,986	$	45,991	$	136,291	$	144,348

The Company offers a comprehensive managed services program, in which the Company manages all or a portion of a client's contingent staffing needs. This service includes both the placement of the Company's own healthcare professionals and the utilization of other staffing agencies to fulfill the client's staffing needs. See additional information in Note (3), “Revenue Recognition.” For the three months ended September 30, 2018 and 2017, revenue under the Company’s managed services program arrangements comprised approximately 61% and 59% for nurse and allied solutions revenue, 17% and 13% for locum tenens solutions revenue and 5% and 7% for other workforce solutions revenue, respectively. For the nine months ended September 30, 2018 and 2017, revenue under the Company’s managed services program arrangements comprised approximately 60% and 57% for nurse and allied solutions revenue, 16% and 12% for locum tenens solutions revenue and 7% and 7% for other workforce solutions revenue, respectively.

The following table summarizes the activity related to the carrying value of goodwill by reportable segment:

	Nurse and Allied Solutions		Locum Tenens Solutions		Other Workforce Solutions		Total
Balance, January 1, 2018	$	103,107	$	19,743	$	217,746	$	340,596
Goodwill from MedPartners acquisition	—		—		81,095		81,095
Goodwill from PDA and LFT acquisition	—		—		16,608		16,608
Balance, September 30, 2018	$	103,107	$	19,743	$	315,449	$	438,299
Accumulated impairment loss as of December 31, 2017 and September 30, 2018	$	154,444	$	53,940	$	6,555	$	214,939

6. NEW CREDIT AGREEMENT

On February 9, 2018, the Company entered into the New Credit Agreement with several lenders to provide for the $400,000 Senior Credit Facility to replace its then-existing credit facilities. The Senior Credit Facility includes a $50,000 sublimit for the issuance of letters of credit and a $50,000 sublimit for swingline loans. The obligations of the Company under the New Credit Agreement and the Senior Credit Facility are secured by substantially all of the assets of the Company. Borrowings under the Senior Credit Facility bear interest at floating rates, at the Company’s option, based upon either LIBOR plus a spread of 1.00% to 2.00% or a base rate plus a spread of 0.00% to 1.00%. The applicable spread is determined quarterly based upon the Company’s consolidated net leverage ratio. The Senior Credit Facility is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The maturity date of the Senior Credit Facility is February 9, 2023.

In connection with obtaining the New Credit Agreement, the Company incurred $2,331 in fees paid to lenders and other third parties, which were capitalized and are amortized to interest expense over the term of the New Credit Facility. In addition,

9

the Company wrote off $574 of unamortized financing fees during the nine months ended September 30, 2018 relating to the

prior credit facilities.

7. FAIR VALUE MEASUREMENT

The Company’s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note 4—Fair Value Measurement” of the 2017 Annual Report. The Company has not changed the valuation techniques or inputs it uses for its fair value measurement, except for its adoption of ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities," during the nine months ended September 30, 2018. See additional information regarding adoption of the new standard in Note (1), “Basis of Presentation” and additional disclosures below.

Assets and Liabilities Measured on a Recurring Basis

The Company’s restricted cash equivalents that serve as collateral for the Company’s outstanding letters of credit

typically consist of money market funds that are measured at fair value based on quoted prices, which are Level 1 inputs.

The Company’s restricted cash equivalents and investments that serve as collateral for the Company’s captive insurance company primarily consist of commercial paper that is measured at observable market prices for identical securities that are traded in less active markets, which are Level 2 inputs. Of the $61,567 commercial paper issued and outstanding as of September 30, 2018, $23,023 had original maturities greater than three months, which were considered available-for-sale securities. As of December 31, 2017, the Company had $28,708 commercial paper issued and outstanding, of which $6,074 had original maturities greater than three months and were considered available-for-sale securities. The increase in commercial paper issued and outstanding is due to additional restricted investments related to the captive insurance company.

The Company’s contingent consideration liabilities are measured at fair value using a probability-weighted discounted cash flow analysis or a simulation-based methodology for the acquired companies, which are Level 3 inputs. The Company recognizes changes to the fair value of its contingent consideration liabilities in selling, general and administrative expenses in the condensed consolidated statements of comprehensive income.

The following tables present information about the above-referenced assets and liabilities and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:

	Fair Value Measurements as of September 30, 2018
	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	2,739		$	2,739	$	—	$	—
Commercial paper	61,567			—		61,567		—
Acquisition contingent consideration liabilities	(8,793		)	—		—		(8,793		)

	Fair Value Measurements as of December 31, 2017
	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	2,713		$	2,713	$	—	$	—
Commercial paper	28,708			—		28,708		—
Acquisition contingent consideration liabilities	(2,070		)	—		—		(2,070		)

10

Level 3 Information

The following tables set forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:

	Three Months Ended September 30,
	2018			2017
Balance as of July 1,	$	(10,119	)	$	(1,932	)
Change in fair value of contingent consideration liability from HealthSource Global Stafffing (“HSG”) acquisition	—			(20		)
Change in fair value of contingent consideration liability from PDA and LFT acquisition	(1,194		)	—
Change in fair value of contingent consideration liability from MedPartners acquisition	2,520			—
Balance as of September 30,	$	(8,793	)	$	(1,952	)

	Nine Months Ended September 30,
	2018			2017
Balance as of January 1,	$	(2,070	)	$	(6,816	)
Settlement of The First String Healthcare contingent consideration liability for year ended December 31, 2016	—			3,000
Settlement of HSG contingent consideration liability for year ended December 31, 2016	70			1,930
Settlement of HSG contingent consideration liability for year ended December 31, 2017	2,000			—
Contingent consideration liability from PDA and LFT acquisition on April 6, 2018	(5,700		)	—
Contingent consideration liability from MedPartners acquisition on April 9, 2018	(4,400		)	—
Change in fair value of contingent consideration liability from HSG acquisition	—			(66		)
Change in fair value of contingent consideration liability from PDA and LFT acquisition	(1,213		)	—
Change in fair value of contingent consideration liability from MedPartners acquisition	2,520			—
Balance as of September 30,	$	(8,793	)	$	(1,952	)

Assets Measured on a Non-Recurring Basis

The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to its goodwill, indefinite-lived intangible assets, long-lived assets, and equity investments.

The Company evaluates goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. The Company determines the fair value of its reporting units based on a combination of inputs, including the market capitalization of the Company, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. The Company determines the fair value of its indefinite-lived intangible assets using the income approach (relief-from-royalty method) based on Level 3 inputs.

The Company’s equity investment represents an investment in a non-controlled corporation without a readily determinable market value. The Company has elected to measure the investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes. The fair value is determined by using quoted prices for identical or similar investments of the same issuer, which are Level 2 inputs. The Company recognizes changes to the fair value of its equity investment in interest expense, net, and other in the condensed consolidated statements of comprehensive income.

11

The following tables set forth a reconciliation of changes in the balance of the equity investment classified as Level 2 in the fair value hierarchy:

	Three Months Ended September 30,
	2018		2017
Balance as of July 1,	$	2,000	$	2,000
Additional investment	4,600		—
Change in fair value	1,359		—
Balance as of September 30,	$	7,959	$	2,000

	Nine Months Ended September 30,
	2018		2017
Balance as of January 1,	$	2,000	$	—
Initial investment	—		2,000
Additional investment	4,600		—
Change in fair value	1,359		—
Balance as of September 30,	$	7,959	$	2,000

There were no triggering events identified, no indication of impairment of the Company’s goodwill, indefinite-lived intangible assets, long-lived assets, or equity investments, and no impairment charges recorded during the nine months ended September 30, 2018 and 2017.

Fair Value of Financial Instruments

The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2018, the Company's senior notes have a carrying amount of $325,000 and an estimated fair value of $314,438. As of December 31, 2017, the senior notes had a carrying amount of $325,000 and an estimated fair value of $335,156. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value. The senior notes were issued in October 2016 and have a fixed rate of 5.125%. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2017 Annual Report.

The fair value of the Company’s long-term self-insurance accruals cannot be estimated as the Company cannot reasonably determine the timing of future payments.

8. INCOME TAXES

The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of September 30, 2018, the Company is no longer subject to state, local or foreign examinations by tax authorities for tax years before 2009, and the Company is no longer subject to U.S. federal income or payroll tax examinations for tax years before 2015. The IRS conducted, completed, and settled audits of the Company’s 2011-2012 and 2013 tax years related to income and employment tax issues for the Company’s treatment of certain non-taxable per diem allowances and travel benefits in November 2017 and May 2018, respectively.

The Company believes its reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years. Notwithstanding the foregoing, the Company could adjust its provision for income taxes and contingent tax liability based on future developments.

Immaterial Tax Correction Related to Prior Periods

During the first quarter of 2018, the Company identified an error related to the income tax treatment of fair value changes in the cash surrender value of its Company Owned Life Insurance (COLI) for prior years. These fair value changes had not previously been included as a net tax benefit in the provision for prior periods. In accordance with ASC 250, Accounting Changes and Error Corrections, management evaluated the materiality of the error from qualitative and quantitative

12

perspectives, and concluded that the error was not material to the consolidated financial statements of prior years, nor is it believed to be material to 2018’s full year consolidated financial statements. As a result, the Company recorded a net tax benefit of $2,501 in the first quarter of 2018 to adjust for this immaterial error correction.

Tax Cuts and Jobs Act

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate from 35% to 21%.

The Tax Act changes that affected the Company in 2017 are primarily tax rate changes on certain deferred tax assets (“DTAs”) and deferred tax liabilities (“DTLs”). The staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.

The Tax Act also establishes new tax laws that will affect 2018 and beyond, including, but not limited to, (1) reduction of the U.S. federal corporate tax rate; (2) the repeal of the domestic production activity deduction; (3) limitations on the deductibility of certain executive compensation; and (4) limitations on various entertainment and meals deductions.

The Company's accounting for the Tax Act is incomplete, primarily relating to executive compensation. However, the Company was able to make reasonable estimates of these elements and, therefore, recorded provisional adjustments for these items. Final adjustments will be made in the quarter ended December 31, 2018 and are not expected to be material.

9. COMMITMENTS AND CONTINGENCIES: LEGAL PROCEEDINGS

From time to time, the Company is involved in various lawsuits, claims, investigations, and proceedings that arise in the ordinary course of business. These matters typically relate to professional liability, tax, compensation, contract, competitor disputes and employee-related matters and include individual and class action lawsuits, as well as inquiries and investigations by governmental agencies regarding the Company’s employment and compensation practices. Additionally, some of the Company’s clients may also become subject to claims, governmental inquiries and investigations, and legal actions relating to services provided by the Company’s healthcare professionals. Depending upon the particular facts and circumstances, the Company may also be subject to indemnification obligations under its contracts with such clients relating to these matters. The Company records a liability when management believes an adverse outcome from a loss contingency is both probable and the amount, or a range, can be reasonably estimated. Significant judgment is required to determine both probability of loss and the estimated amount. The Company reviews its loss contingencies at least quarterly and adjusts its accruals and/or disclosures to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, or other new information, as deemed necessary. The most significant matters for which the Company has established loss contingencies are class actions related to wage and hour claims under California and Federal law. Specifically, among other claims in these lawsuits, it is alleged that employees were not afforded required breaks or compensated for all time worked, employees' wage statements are not sufficiently clear, and certain expense reimbursements should be included in the regular rate of pay for purposes of calculating overtime rates. The Company believes that its wage and hour practices conform with law in all material respects, but litigation is always subject to inherent uncertainty. As a result, the Company entered into settlement agreements relating to claims in two wage and hour class actions during September and October 2018. The settlement agreements are subject to court approval, which is considered probable. The Company recorded increases to its accruals established in connection with these matters amounting to $12,140 during the three months ended September 30, 2018.

With regard to outstanding loss contingencies as of September 30, 2018, which are included in accounts payable and accrued expenses in the condensed consolidated balance sheet, the Company believes that such matters will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.

13

10. BALANCE SHEET DETAILS

The consolidated balance sheets detail is as follows as of September 30, 2018 and December 31, 2017:

	September 30, 2018			December 31, 2017
Other current assets:
Restricted cash and cash equivalents	$	22,227		$	25,506
Income tax receivable	2,901			15,898
Other	10,230			9,589
Other current assets	$	35,358		$	50,993
Fixed assets:
Furniture and equipment	$	32,814		$	29,494
Software	155,534			132,770
Leasehold improvements	8,315			9,056
	196,663			171,320
Accumulated depreciation	(109,846		)	(97,889		)
Fixed assets, net	$	86,817		$	73,431
Other assets:
Life insurance cash surrender value	$	58,576		$	48,145
Other	34,630			26,221
Other assets	$	93,206		$	74,366
Accounts payable and accrued expenses:
Trade accounts payable	$	21,217		$	31,420
Subcontractor payable	46,276			41,786
Accrued expenses	37,802			29,238
Loss contingencies	25,042			12,548
Professional liability reserve	8,510			7,672
Other	3,696			7,655
Accounts payable and accrued expenses	$	142,543		$	130,319
Accrued compensation and benefits:
Accrued payroll	$	39,665		$	33,923
Accrued bonuses	18,795			19,489
Accrued travel expense	3,618			3,256
Health insurance reserve	3,820			3,658
Workers compensation reserve	7,789			8,553
Deferred compensation	59,502			49,330
Other	2,443			3,214
Accrued compensation and benefits	$	135,632		$	121,423
Other long-term liabilities:
Workers compensation reserve	$	19,387		$	19,074
Professional liability reserve	37,847			38,964
Deferred rent	15,053			14,744
Unrecognized tax benefits	4,221			5,270
Deferred revenue	994			960
Other	25			267
Other long-term liabilities	$	77,527		$	79,279

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results

of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on February 16, 2018 (“2017 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.

Overview of Our Business

We provide healthcare workforce solutions and staffing services to healthcare facilities across the nation. As an innovative workforce solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” workforce consulting services, predictive modeling, staff scheduling, mid-revenue cycle solutions and the placement of physicians, nurses, allied healthcare professionals and healthcare leaders into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment.

We conduct business through three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. For the three months ended September 30, 2018, we recorded revenue of $526.8 million, as compared to $494.4 million for the same period last year. For the three months ended September 30, 2018, we recorded net income of $27.9 million, as compared to $28.1 million for the same period last year. For the nine months ended September 30, 2018, we recorded revenue of $1,607.4 million, as compared to $1,479.4 million for the same period last year. For the nine months ended September 30, 2018, we recorded net income of $106.1 million, as compared to $91.4 million for the same period last year.

Nurse and allied solutions segment revenue comprised 61% and 62% of total consolidated revenue for the nine months ended September 30, 2018 and 2017, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all of the temporary nursing and allied staffing needs of a client and traditional clinical staffing solutions of variable assignment lengths.

Locum tenens solutions segment revenue comprised 19% and 22% of total consolidated revenue for the nine months ended September 30, 2018 and 2017, respectively. Through our locum tenens solutions segment, we provide a comprehensive managed services solution in which we manage all of the locum tenens needs of a client and place physicians of all specialties, as well as dentists and advanced practice providers, with clients on a temporary basis as independent contractors. These locum tenens providers are used by our clients to fill temporary vacancies created by vacation and leave schedules and to bridge the gap while they seek permanent candidates or explore expansion. Our locum tenens clients represent a diverse group of healthcare organizations throughout the United States, including hospitals, health systems, medical groups, occupational medical clinics, psychiatric facilities, government institutions, and insurance entities. The professionals we place are recruited nationwide and are typically placed on contracts with assignment lengths ranging from a few days to one year.

Other workforce solutions segment revenue comprised 20% and 16% of total consolidated revenue for the nine months ended September 30, 2018 and 2017, respectively. Through our other workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) identifying and recruiting physicians and healthcare leaders for permanent placement, (2) placing interim leaders and executives across all healthcare settings, (3) a software-as-a-service (“SaaS”) VMS through which our clients can manage all of their temporary staffing needs, (4) RPO services that leverage our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent placement needs, (5) an education program that provides custom healthcare education, research, professional practice tools, and professional development services, (6) mid-revenue cycle management and related consulting services, and (7) workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology.

As part of our long-term growth strategy to add value for our clients, healthcare professionals, and shareholders, on April 6, 2018 and April 9, 2018, we acquired Phillips DiPisa and Leaders For Today (“PDA and LFT” or “PDA/LFT”) and MedPartners HIM (“MedPartners”), respectively. PDA and LFT offer a range of leadership staffing and permanent placement solutions for the healthcare industry. MedPartners provides mid-revenue cycle management solutions, including case

15

management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. See additional information in the accompanying Note (2), “Acquisitions.”

Recent Trends

Demand for our temporary and permanent placement staffing services is driven in part by U.S. economic and labor trends.

The U.S. Bureau of Labor Statistics’ survey data reflects near record levels of healthcare job openings and quits. We view this data, along with a nearly 20-year-low unemployment rate and continued economic growth as positive trends for the healthcare staffing industry. The low unemployment rate has led to some wage growth to attract healthcare professionals.

The increasing consolidation within the healthcare industry is creating larger, more sophisticated and complex health systems that we believe has elevated the need for strategic workforce solutions capable of partnering to solve their recruiting, staffing and workforce optimization requirements. Given the increasing need for partners capable of offering a comprehensive workforce solution, we continue to see the benefits of our workforce solutions strategy, particularly with our MSPs. As a result of our ongoing focus on these strategic MSP relationships, the percentage of our staffing revenue derived from our MSP clients continues to increase.

In our nurse and allied solutions segment, although clients have focused this year on hiring more permanent staff and increasing the utilization of their staff, overall demand for our travel nurse staffing business has been improving and our nurse orders are now trending above prior year levels. Although we continue to negotiate bill rate increases, a reduced mix of nursing placements utilizing premium bill rates has lowered the overall average bill rates in this business.

In our locum tenens solutions segment, in late 2017 and in the first half of 2018 we made operating model changes and implemented new front and back office technologies. Although these changes are expected to have a long-term positive impact on our growth and profitability, they continue to be disruptive to our current sales productivity and revenue. We believe the overall demand environment for locum tenens is relatively stable and that client interest in managed service programs is increasing.

In our other workforce solutions segment, our permanent placement, mid-revenue cycle and workforce consulting businesses are growing, but continue to be offset by lower revenue in our vendor management systems business.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. There have been no material changes in our critical accounting policies and estimates, other than the adoption of the Accounting Standards Updates (“ASUs”) described in Item 1. Condensed Consolidated Financial Statements—Note 1, “Basis of Presentation,” as compared to the critical accounting policies and estimates described in our 2017 Annual Report.

16

Results of Operations

The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. The MedPartners and PDA/LFT acquisitions impact the comparability of the results between the three and nine months ended September 30, 2018 and 2017 depending on the timing of the applicable acquisition. Our historical results are not necessarily indicative of our future results of operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Unaudited Condensed Consolidated Statements of Operations:
Revenue	100.0	%	100.0	%	100.0	%	100.0	%
Cost of revenue	66.8		67.7		67.4		67.4
Gross profit	33.2		32.3		32.6		32.6
Selling, general and administrative	23.0		20.3		21.2		20.2
Depreciation and amortization	2.1		1.7		1.9		1.6
Income from operations	8.1		10.3		9.5		10.8
Interest expense, net, and other	0.9		1.0		1.0		1.0
Income before income taxes	7.2		9.3		8.5		9.8
Income tax expense	1.9		3.6		1.9		3.6
Net income	5.3	%	5.7	%	6.6	%	6.2	%

Comparison of Results for the Three Months Ended September 30, 2018 to the Three Months Ended September 30, 2017

Revenue. Revenue increased7% to $526.8 million for the three months ended September 30, 2018 from $494.4 million for the same period in 2017, primarily attributable to additional revenue of $38.2 million from our PDA/LFT and MedPartners acquisitions. Excluding the additional revenue from acquisitions, revenue decreased 1%.

Nurse and allied solutions segment revenue increased1% to $306.3 million for the three months ended September 30, 2018 from $302.9 million for the same period in 2017. The $3.4 millionincrease was primarily attributable to a 2% increase in the average number of healthcare professionals on assignment, partially offset by a lower average bill rate during the three months ended September 30, 2018.

Locum tenens solutions segment revenue decreased9% to $101.1 million for the three months ended September 30, 2018 from $111.4 million for the same period in 2017. The $10.3 milliondecrease was primarily attributable to a 15% decrease in the number of days filled during the three months ended September 30, 2018, partially offset by a 7% increase in the revenue per day filled.

Other workforce solutions segment revenue increased49% to $119.4 million for the three months ended September 30, 2018 from $80.1 million for the same period in 2017. Of the $39.3 millionincrease, $38.2 million was attributable to additional revenue in connection with the PDA/LFT and MedPartners acquisitions, with the remainder primarily attributable to growth in our permanent placement, mid-revenue cycle and workforce consulting businesses, partially offset by a decline in our interim leadership and VMS businesses during the three months ended September 30, 2018.

Gross Profit. Gross profit increased10% to $175.1 million for the three months ended September 30, 2018 from $159.5 million for the same period in 2017, representing gross margins of 33.2% and 32.3%, respectively. The gross margin for the three months ended September 30, 2018 was positively impacted by higher-than-average gross margins from PDA/LFT and MedPartners and a change in our physician permanent placement business model that prompted a $3.3 million classification of certain recruiter compensation expenses to SG&A (as defined below) that was previously in cost of revenue. Net of these factors, our year-over-year gross margin declined primarily due to a lower margin in our locum tenens solutions segment. Gross margin by reportable segment for the three months ended September 30, 2018 and 2017 was 27.4% and 27.3% for nurse and allied solutions, 28.4% and 30.1% for locum tenens solutions, and 52.4% and 54.1% for other workforce solutions, respectively. The other workforce solutions segment decrease during the three months ended September 30, 2018 was primarily due to the change in sales mix resulting from the additions of PDA/LFT and MedPartners.

17

Selling, General and Administrative Expenses. Selling, general and administrative (“SG&A”) expenses were $121.2 million, representing 23.0% of revenue, for the three months ended September 30, 2018, as compared to $100.6 million, representing 20.3% of revenue, for the same period in 2017. The increase in SG&A expenses was primarily due to $8.7 million of additional SG&A expenses from the PDA/LFT and MedPartners acquisitions and a $12.1 million increase in accruals related to the probable settlements of two legal matters. The year-over-year increase in SG&A expenses in unallocated corporate overhead was primarily driven by the increase in legal accruals during the three months ended September 30, 2018. See additional information in the accompanying Note (9), “Commitments and Contingencies: Legal Proceedings.” SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

	(In Thousands) Three Months Ended September 30,
	2018		2017
Nurse and allied solutions	$	41,643	$	41,884
Locum tenens solutions	17,762		19,075
Other workforce solutions	33,575		23,445
Unallocated corporate overhead	26,427		13,698
Share-based compensation	1,809		2,477
	$	121,216	$	100,579

Depreciation and Amortization Expenses. Amortization expense increased 43% to $6.7 million for the three months ended September 30, 2018 from $4.7 million for the same period in 2017, with the increase attributable to additional amortization expenses related to the intangible assets acquired in the PDA/LFT and MedPartners acquisitions. Depreciation expense increased 35% to $4.6 million for the three months ended September 30, 2018 from $3.4 million for the same period in 2017, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.

Interest Expense, Net, and Other. Interest expense, net, and other, was $4.6 million during the three months ended September 30, 2018 as compared to $4.8 million for the same period in 2017. The decrease is primarily due to a $1.4 million gain related to the change in fair value of an equity investment, partially offset by higher average debt outstanding balance for the three months ended September 30, 2018, which resulted from borrowings used to finance the MedPartners acquisition.

Income Tax Expense. Income tax expense was $10.1 million for the three months ended September 30, 2018 as compared to $17.9 million for the same period in 2017, reflecting effective income tax rates of 27% and 39% for the three months ended September 30, 2018 and 2017, respectively. The difference in the effective income tax rate was primarily attributable to the impact of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) which reduced the U.S. federal corporate tax rate from 35% to 21%, effective 2018. The decrease in the rate was partially offset by provisions of the Tax Act which disallowed certain fringe benefits, meals and entertainment deductions and performance based compensation for covered employees (Chief Executive Officer, Chief Financial Officer and the top three highest paid executive officers). We currently estimate our annual effective income tax rate to be approximately 24% for 2018.

Comparison of Results for the Nine Months Ended September 30, 2018 to the Nine Months Ended September 30, 2017

Revenue. Revenue increased9% to $1,607.4 million for the nine months ended September 30, 2018 from $1,479.4 million for the same period in 2017, primarily attributable to additional revenue of $73.8 million from our PDA/LFT and MedPartners acquisitions with the remainder of the increase driven by 4% organic growth.

Nurse and allied solutions segment revenue increased7% to $977.2 million for the nine months ended September 30, 2018 from $917.2 million for the same period in 2017. The $60.0 millionincrease was primarily attributable to an approximately $24.0 million increase in labor disruption revenue and a 4% increase in the average number of healthcare professionals on assignment, partially offset by a 2% decrease in the average bill rate during the nine months ended September 30, 2018.

Locum tenens solutions segment revenue decreased3% to $311.5 million for the nine months ended September 30, 2018 from $322.5 million for the same period in 2017. The $11.0 milliondecrease was primarily attributable to a 9% decrease in the number of days filled during the nine months ended September 30, 2018, partially offset by a 6% increase in the revenue per day filled.

Other workforce solutions segment revenue increased33% to $318.7 million for the nine months ended September 30, 2018 from $239.7 million for the same period in 2017. Of the $79.0 millionincrease, $73.8 million was attributable to

18

additional revenue in connection with the PDA/LFT and MedPartners acquisitions, with the remainder primarily attributable to growth in our interim leadership, mid-revenue cycle management and workforce consulting businesses, partially offset by declines in our permanent placement and VMS businesses during the nine months ended September 30, 2018.

Gross Profit. Gross profit increased9% to $523.9 million for the nine months ended September 30, 2018 from $482.3 million for the same period in 2017, representing gross margins of 32.6% for both periods. The gross margin for the nine months ended September 30, 2018 was positively impacted by higher-than-average gross margins from PDA/LFT and MedPartners and a change in our physician permanent placement business model that prompted a $6.5 million classification of certain recruiter compensation expenses to SG&A that was previously in cost of revenue. These positives were partly offset by a below-average labor disruption gross margin. Net of these factors, our year-over-year gross margin declined primarily due to a lower margin in our locum tenens solutions segment. Gross margin by reportable segment for the nine months ended September 30, 2018 and 2017 was 27.2% and 27.6% for nurse and allied solutions, 29.0% and 30.2% for locum tenens solutions, and 52.6% and 54.9% for other workforce solutions, respectively. The other workforce solutions segment decrease during the nine months ended September 30, 2018 was primarily due to the change in sales mix resulting from the additions of PDA/LFT and MedPartners.

Selling, General and Administrative Expenses. SG&A expenses were $341.5 million, representing 21.2% of revenue, for the nine months ended September 30, 2018, as compared to $299.3 million, representing 20.2% of revenue, for the same period in 2017. The increase in SG&A expenses was primarily due to $16.2 million of additional SG&A expenses from the PDA/LFT and MedPartners acquisitions, a $12.1 million increase in accruals related to the probable settlements of two legal matters, $2.1 million lower actuarial-based decrease in our professional liability reserves as compared to the same period in 2017 and other expenses associated with our revenue growth. The year-over-year increase in SG&A expenses in the nurse and allied solutions segment was primarily driven by additional expenses to support the labor disruption revenue during the nine months ended September 30, 2018 and additional employee and insurance expenses associated with the revenue growth. The year-over-year increase in SG&A expenses in unallocated corporate overhead was primarily driven by the increase in legal accruals during the nine months ended September 30, 2018. See additional information in the accompanying Note (9), “Commitments and Contingencies: Legal Proceedings.” SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

	(In Thousands) Nine Months Ended September 30,
	2018		2017
Nurse and allied solutions	$	128,107	$	118,464
Locum tenens solutions	55,930		58,507
Other workforce solutions	90,226		69,902
Unallocated corporate overhead	59,271		44,732
Share-based compensation	7,954		7,720
	$	341,488	$	299,325

Depreciation and Amortization Expenses. Amortization expense increased 27% to $17.6 million for the nine months ended September 30, 2018 from $13.9 million for the same period in 2017, with the increase attributable to additional amortization expenses related to the intangible assets acquired in the PDA/LFT and MedPartners acquisitions. Depreciation expense increased 24% to $12.2 million for the nine months ended September 30, 2018 from $9.8 million for the same period in 2017, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.

Interest Expense, Net, and Other. Interest expense, net, and other, was $16.4 million during the nine months ended September 30, 2018 as compared to $14.9 million for the same period in 2017. The increase is primarily due to the write-off of unamortized deferred financing fees in connection with the refinancing of our prior credit facilities during the first quarter of 2018 and a higher average debt outstanding balance for the nine months ended September 30, 2018, which resulted from borrowings used to finance the MedPartners acquisition. See additional information in the accompanying Note (6), “New Credit Agreement.” The overall increase is partially offset by a $1.4 million gain related to the change in fair value of an equity investment during the nine months ended September 30, 2018.

Income Tax Expense. Income tax expense was $30.2 million for the nine months ended September 30, 2018 as compared to income tax expense of $53.0 million for the same period in 2017, reflecting effective income tax rates of 22% and 37% for the nine months ended September 30, 2018 and 2017, respectively. The difference in the effective income tax rate was primarily attributable to the impact of the Tax Act which reduced the U.S. federal corporate tax rate from 35% to 21%, effective

19

2018. In addition, the Company recorded a net tax benefit of $3.0 million during the nine months ended September 30, 2018 to adjust for the tax treatment of fair value changes in the cash surrender value of its Company Owned Life Insurance (“COLI”). See accompanying Note (8), "Income Taxes" for discussion of immaterial tax correction related to prior periods. The decrease in the rate was partially offset by provisions of the Tax Act which disallowed certain fringe benefits, meals and entertainment deductions and performance based compensation for covered employees (Chief Executive Officer, Chief Financial Officer and the top three highest paid executive officers). We currently estimate our annual effective income tax rate to be approximately 24% for 2018. The 22% effective tax rate in the nine months ended September 30, 2018 differs from our estimated annual effective income tax rate of 24% primarily due to a discrete tax benefit of $5.1 million in the nine months ended September 30, 2018 relating to the application of ASU 2016-09, “Stock Compensation - Improvements to Employee Share-Based Payment Accounting” and the net tax benefit recorded in the nine months ended September 30, 2018 relating to COLI as discussed above. We have described ASU 2016-09 in further detail in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (1)(r), Recently Adopted Accounting Pronouncements” of our 2017 Annual Report on Form 10-K.

Liquidity and Capital Resources

In summary, our cash flows were:

	(In Thousands) Nine Months Ended September 30,
	2018			2017 *As Adjusted
Net cash provided by operating activities	$	168,046		$	102,096
Net cash used in investing activities	(271,648		)	(24,045		)
Net cash provided by (used in) financing activities	81,774			(63,824		)

* See Note (1) to the accompanying Condensed Consolidated Financial Statements, “Basis of Presentation” for a summary of adjustments resulting from the adoption of ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash.”

Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and the Notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities. During the third quarter of 2017, we paid off the remaining balance of our term debt. On February 9, 2018, we replaced our then-existing credit agreement with our New Credit Agreement (as defined below). As of September 30, 2018, $150 million was drawn with $239.8 million of available credit under the Senior Credit Facility (as defined below) and the aggregate principal amount of our 5.125% Senior Notes due 2024 (the “Notes”) outstanding equaled $325.0 million. We describe in further detail our New Credit Agreement, under which our Senior Credit Facility is governed, and the Notes in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2017 Annual Report on Form 10-K.

We believe that cash generated from operations and available borrowings under our Senior Credit Facility will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under our Senior Credit Facility or other borrowings under our New Credit Agreement, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.

Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2018 was $168.0 million, compared to $102.1 million for the same period in 2017. The increase in net cash provided by operating activities was primarily attributable to (1) improved operating results, (2) a decrease in income taxes receivable, and (3) increases in accounts payable and accrued expenses as well as accrued compensation and benefits between periods due to timing of payments. The overall increase was partially offset by a decrease in other liabilities and an increase in other current assets between periods. Our Days Sales Outstanding (“DSO”) was 64 days at September 30, 2018, 63 days at December 31, 2017, and 64 days at September 30, 2017.

Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2018 was $271.6 million, compared to $24.0 million for the same period in 2017. The increase was primarily due to (1) $217.4 million used for acquisitions during the nine months ended September 30, 2018, as compared to no cash paid for acquisitions during the nine months ended September

20

30, 2017, and (2) a net purchase of restricted investments related to our captive insurance company of $16.8 million during the nine months ended September 30, 2018, as compared to net proceeds of $6.2 million during the nine months ended September 30, 2017. See additional information in the accompanying Note (2), “Acquisitions.” Capital expenditures were $23.9 million and $17.2 million for the nine months ended September 30, 2018 and 2017, respectively.

Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2018 was $81.8 million, primarily due to borrowings of $195.0 million under the Senior Credit Facility (as defined below), partially offset by (1) the repayment of $45.0 million under the Senior Credit facility, (2) $52.8 million paid in connection with the repurchase of our common stock, (3) $2.3 million payment of financing costs in connection with the new credit agreement, (4) $1.7 million for prior acquisition contingent consideration earn-out payments, and (5) $11.4 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards. Net cash used in financing activities during the nine months ended September 30, 2017 was $63.8 million, primarily due to (1) the repayment of $44.1 million under our then-existing term loan, (2) $3.7 million for prior acquisitions contingent consideration earn-out payments, (3) $7.1 million paid in connection with the repurchase of our common stock, and (4) $9.1 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards.

New Credit Agreement

On February 9, 2018, we entered into a credit agreement (the “New Credit Agreement”) with several lenders to provide for a $400 million secured revolving credit facility (the “Senior Credit Facility”) to replace our then-existing Credit Agreement. The Senior Credit Facility includes a $50 million sublimit for the issuance of letters of credit and a $50 million sublimit for swingline loans. Our obligations under the New Credit Agreement and the Senior Credit Facility are secured by substantially all of our assets. Borrowings under the Senior Credit Facility bear interest at floating rates, at our option, based upon either LIBOR plus a spread of 1.00% to 2.00% or a base rate plus a spread of 0.00% to 1.00%. The applicable spread is determined quarterly based upon our consolidated net leverage ratio. The Senior Credit Facility is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The maturity date of the Senior Credit Facility is February 9, 2023.

In connection with obtaining the New Credit Agreement, we incurred $2.3 million in fees paid to lenders and other third parties, which were capitalized and are amortized to interest expense over the term of the Senior Credit Facility. In addition, we wrote off $0.6 million of unamortized financing fees during the nine months ended September 30, 2018 related to our prior credit facilities. To help finance the MedPartners acquisition, we borrowed $195.0 million from the Senior Credit Facility in April 2018. We paid down $45 million during the nine months ended September 30, 2018. The acquisition is more fully described in Note (2) to the accompanying Condensed Consolidated Financial Statements, “Acquisitions.”

Letters of Credit

At September 30, 2018, we maintained outstanding standby letters of credit totaling $12.9 million as collateral in relation to our workers’ compensation insurance agreements and a corporate office lease agreement. Of the $12.9 million of outstanding letters of credit, we have collateralized $2.7 million in cash and cash equivalents and the remaining amounts are collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2017 totaled $22.0 million.

Off-Balance Sheet Arrangements

At September 30, 2018, we did not have any off-balance sheet arrangement that has or is reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

Contractual Obligations

There have been no material changes during the nine months ended September 30, 2018, other than the New Credit Agreement described in the accompanying Note (6), “New Credit Agreement” and the associated borrowings, to the table entitled “Contractual Obligations” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth in our 2017 Annual Report.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, “Leases.” This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also will require disclosures to help investors and other

21

financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The ASU becomes effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are in the process of analyzing the impact of this standard and evaluating the impact on our consolidated financial statements. This includes reviewing current accounting policies and practices to identify potential differences that would result from applying the requirements under the new standard. We completed our preliminary evaluation of the impact of this standard, including assessing the completeness of the lease population and analyzing the practical expedients. We expect to complete the evaluation of the impact of the accounting and disclosure requirements on our business processes, controls and systems by the end of 2018. The FASB recently issued guidance that provides an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in Accounting Standards Codification 840, Leases, including its disclosure requirements, in the comparative periods presented. We will adopt this standard in the first quarter of 2019, and plan to apply the optional transition method and optional practical expedients. The adoption of this standard, which is subject to the completion of our assessment, will result in a significant increase to our consolidated balance sheet for lease liabilities and right-of-use assets.

In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” The standard simplifies the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Further, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019, with early adoption permitted for impairment tests performed after January 1, 2017. While we continue to assess the timing of adopting this standard, we do not expect the adoption of this standard to have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The standard modifies the current disclosure requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We are currently evaluating the timing of this new standard’s adoption and the effect that adopting it will have on our disclosures.

There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 2017 Annual Report and include but are not limited to:

• the effects of economic downturns or slow recoveries, which could result in less demand for our services and pricing pressures;

• any inability on our part to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs;

• the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts with our clients;

• the level of consolidation and concentration of buyers of healthcare workforce solutions and staffing services, which could affect the pricing of our services and our ability to mitigate concentration risk;

22

• the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting or otherwise, which may negatively affect our revenue, results of operations, and cash flows;

• the repeal or significant erosion of the Patient Protection and Affordable Care Act without a corresponding replacement may negatively affect the demand for our services;

• any inability on our part to grow and operate our business profitably in compliance with federal and state healthcare industry regulation, including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting; 

• any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;

• the effect of investigations, claims, and legal proceedings alleging medical malpractice, violation of employment and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;

• security breaches and other disruptions that could compromise our information and expose us to liability, which could cause our business and reputation to suffer and could subject us to substantial liabilities;

• any technology disruptions or our inability to implement new infrastructure and technology systems effectively may adversely affect our operating results and our ability to manage our business effectively;

• disruption to or failures of our SaaS-based technology within certain of our service offerings or our inability to adequately protect our intellectual property rights with respect to such technology, which could reduce client satisfaction, harm our reputation, and negatively affect our business;

• the effect of cybersecurity risks and cyber incidents, which could adversely affect our business and disrupt our operations;

• any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs, which could increase our operating costs and negatively affect our business and profitability;

• any inability on our part to properly screen and match quality healthcare professionals with suitable placements, which may adversely affect demand for our services;

• any inability on our part to successfully attract, develop and retain a sufficient number of quality sales and operations personnel;

• our increasing dependence on third parties for the execution of certain critical functions;

• the loss of our key officers and management personnel, which could adversely affect our business and operating results;

• any inability to consummate and effectively integrate acquisitions into our business operations may adversely affect our long-term growth and our results of operations;

• any inability on our part to maintain our positive brand awareness and identity;

• any recognition by us of an impairment to the substantial amount of goodwill or indefinite-lived intangibles on our balance sheet;

• our substantial indebtedness and any inability on our part to generate sufficient cash flow to service our debt, which could adversely affect our ability to raise additional capital to fund operations and limit our ability to react to changes in the economy or our industry;

• the terms of our debt instruments that impose restrictions on us that may affect our ability to successfully operate our business; and

• the effect of significant adverse adjustments by us to our insurance-related accruals, which could decrease our earnings or increase our losses, as the case may be.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three and nine months ended September 30, 2018, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments. A 100 basis point increase

23

in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2018. During the three and nine months ended September 30, 2018, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.

Item 4. Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 2018 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

24

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2017 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

25

Item 6. Exhibits

Exhibit Number	Description
31.1	Certification by Susan R. Salka pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.*
31.2	Certification by Brian M. Scott pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.*
32.1	Certification by Susan R. Salka pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2	Certification by Brian M. Scott pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS	XBRL Instance Document.*
101.SCH	XBRL Taxonomy Extension Schema Document.*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.*

* Filed herewith.

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 2, 2018

AMN HEALTHCARE SERVICES, INC.

/S/    SUSAN R. SALKA

Susan R. Salka

President and Chief Executive Officer

(Principal Executive Officer)

Date: November 2, 2018

/S/    BRIAN M. SCOTT

Brian M. Scott

Chief Accounting Officer,

Chief Financial Officer and Treasurer

(Principal Accounting and Financial Officer)

27

EX-31.1

Exhibit 31.1

Certification Pursuant To

Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Susan R. Salka, certify that:

1. I have reviewed this report on Form 10-Q of AMN Healthcare Services, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/S/    SUSAN R. SALKA

Susan R. Salka

Director, President and Chief Executive Officer

(Principal Executive Officer)

Date: November 2, 2018

EX-31.2

Exhibit 31.2

Certification Pursuant To

Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Brian M. Scott, certify that:

1. I have reviewed this report on Form 10-Q of AMN Healthcare Services, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/S/    BRIAN M. SCOTT

Brian M. Scott

Chief Accounting Officer,

Chief Financial Officer and Treasurer

(Principal Accounting and Financial Officer)

Date: November 2, 2018

EX-32.1

Exhibit 32.1

AMN Healthcare Services, Inc.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AMN Healthcare Services, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Susan R. Salka, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/    SUSAN R. SALKA

Susan R. Salka
Director, President and Chief Executive Officer
(Principal Executive Officer)

Date: November 2, 2018

EX-32.2

Exhibit 32.2

AMN Healthcare Services, Inc.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AMN Healthcare Services, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian M. Scott, Chief Accounting Officer, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/    BRIAN M. SCOTT

Brian M. Scott
Chief Accounting Officer,
Chief Financial Officer and Treasurer
(Principal Accounting and Financial Officer)

Date: November 2, 2018

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 31, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	AMN HEALTHCARE SERVICES INC
Entity Central Index Key	0001142750
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding (excluding treasury shares)		46,867,877

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 18,614	$ 15,147
Accounts receivable, net of allowances of $9,741 and $9,801 at September 30, 2018 and December 31, 2017, respectively	366,436	350,496
Accounts receivable, subcontractor	44,891	41,012
Prepaid expenses	14,540	16,505
Other current assets	35,358	50,993
Total current assets	479,839	474,153
Restricted cash, cash equivalents and investments	59,453	64,315
Fixed assets, net of accumulated depreciation of $109,846 and $97,889 at September 30, 2018 and December 31, 2017, respectively	86,817	73,431
Other assets	93,206	74,366
Goodwill	438,299	340,596
Intangible assets, net of accumulated amortization of $108,283 and $90,685 at September 30, 2018 and December 31, 2017, respectively	332,788	227,096
Total assets	1,490,402	1,253,957
Current liabilities:
Accounts payable and accrued expenses	142,543	130,319
Accrued compensation and benefits	135,632	121,423
Deferred revenue	13,107	8,384
Other current liabilities	11,806	5,146
Total current liabilities	303,088	265,272
Revolving credit facility	150,000	0
Notes payable, less unamortized fees	320,416	319,843
Deferred income taxes, net	24,651	27,036
Other long-term liabilities	77,527	79,279
Total liabilities	875,682	691,430
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 10,000 shares authorized; none issued and outstanding at September 30, 2018 and December 31, 2017	0	0
Common stock, $0.01 par value; 200,000 shares authorized; 48,809 issued and 46,914 outstanding at September 30, 2018 and 48,411 issued and 47,481 outstanding at December 31, 2017	488	484
Additional paid-in capital	449,868	453,351
Treasury stock, at cost (1,895 and 930 shares at September 30, 2018 and December 31, 2017, respectively)	(86,175)	(33,425)
Retained earnings	250,446	142,229
Accumulated other comprehensive income (loss)	93	(112)
Total stockholders’ equity	614,720	562,527
Total liabilities and stockholders’ equity	$ 1,490,402	$ 1,253,957

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 9,741	$ 9,801
Accumulated depreciation	109,846	97,889
Accumulated amortization	$ 108,283	$ 90,685
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	48,809,000	48,411,000
Common stock, shares outstanding (in shares)	46,914,000	47,481,000
Treasury stock (in shares)	1,895,000	930,000

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Revenue	$ 526,842	$ 494,406	$ 1,607,439	$ 1,479,378
Cost of revenue	351,695	334,867	1,083,512	997,051
Gross profit	175,147	159,539	523,927	482,327
Operating expenses:
Selling, general and administrative	121,216	100,579	341,488	299,325
Depreciation and amortization	11,296	8,132	29,788	23,759	[1]
Total operating expenses	132,512	108,711	371,276	323,084
Income from operations	42,635	50,828	152,651	159,243
Interest expense, net, and other	4,649	4,837	16,360	14,895
Income before income taxes	37,986	45,991	136,291	144,348
Income tax expense	10,068	17,863	30,163	52,957
Net income	27,918	28,128	106,128	91,391	[1]
Other comprehensive income (loss):
Foreign currency translation and other	133	(73)	205	(111)
Cash flow hedge, net of income taxes	0	0	0	(15)
Other comprehensive income (loss)	133	(73)	205	(126)
Comprehensive income	$ 28,051	$ 28,055	$ 106,333	$ 91,265
Net income per common share:
Basic (in dollars per share)	$ 0.59	$ 0.59	$ 2.23	$ 1.91
Diluted (in dollars per share)	$ 0.58	$ 0.57	$ 2.17	$ 1.85
Weighted average common shares outstanding:
Basic (shares)	47,286	47,912	47,556	47,870
Diluted (shares)	48,529	49,445	48,859	49,480

[1] See Note (1) for a summary of adjustments.

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	[1]
Cash flows from operating activities:
Net income	$ 106,128	$ 91,391
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	29,788	23,759
Non-cash interest expense and other	591	1,718
Write-off of fees on the prior credit facilities	574	0
Change in fair value of contingent consideration	(1,307)	66
Increase in allowances for doubtful accounts and sales credits	6,240	9,012
Provision for deferred income taxes	(2,384)	(9,512)
Share-based compensation	7,954	7,720
Loss on disposal or sale of fixed assets	40	130
Amortization of discount on investments	(78)	(112)
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable	743	(10,631)
Accounts receivable, subcontractor	(3,879)	12,033
Income taxes receivable	12,997	(1,854)
Prepaid expenses	2,334	(1,643)
Other current assets	446	6,100
Other assets	(1,019)	(5,204)
Accounts payable and accrued expenses	7,311	(20,442)
Accrued compensation and benefits	11,014	3,991
Other liabilities	(10,423)	(5,112)
Deferred revenue	1,062	678
Restricted investments balance	(86)	8
Net cash provided by operating activities	168,046	102,096
Cash flows from investing activities:
Purchase and development of fixed assets	(23,922)	(17,168)
Purchase of investments	(27,185)	(11,021)
Proceeds from maturity of investments	10,400	17,200
Payments to fund deferred compensation plan	(7,800)	(10,056)
Equity investment	(4,600)	(2,000)
Cash paid for acquisitions, net of cash received	217,361	0
Cash paid for other intangibles	(1,180)	0
Cash paid for working capital adjustments and holdback liability for prior year acquisitions	0	(1,000)
Net cash used in investing activities	(271,648)	(24,045)
Cash flows from financing activities:
Payments on term loans	0	(44,063)
Payments on revolving credit facility	(45,000)	0
Proceeds from revolving credit facility	195,000	0
Repurchase of common stock	(52,750)	(7,097)
Payment of financing costs	(2,331)	0
Earn-out payments for prior acquisitions	(1,713)	(3,677)
Proceeds from termination of derivative contract	0	85
Cash paid for shares withheld for taxes	(11,432)	(9,072)
Net cash provided by (used in) financing activities	81,774	(63,824)
Effect of exchange rate changes on cash	205	(111)
Net increase (decrease) in cash, cash equivalents and restricted cash	(21,623)	14,116
Cash, cash equivalents and restricted cash at the beginning of period	98,894	51,028
Cash, cash equivalents and restricted cash at the end of period	77,271	65,144
Supplemental disclosures of cash flow information:
Cash paid for interest (net of $368 and $113 capitalized for the nine months ended September 30, 2018 and 2017, respectively)	11,521	9,395
Cash paid for income taxes	21,223	65,998
Acquisitions:
Fair value of tangible assets acquired in acquisitions, net of cash received	24,027	0
Goodwill	97,703	0
Intangible assets	122,111	0
Liabilities assumed	(16,380)	0
Earn-out liabilities	(10,100)	0
Supplemental disclosures of non-cash investing and financing activities:
Purchase of fixed assets recorded in accounts payable and accrued expenses	$ 4,504	$ 3,156

[1] See Note (1) for a summary of adjustments.

XML

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Statement of Cash Flows [Abstract]
Interest capitalized	$ 368	$ 113

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

BASIS OF PRESENTATION

The condensed consolidated balance sheets and related condensed consolidated statements of comprehensive income and cash flows contained in this Quarterly Report on Form 10-Q (this “Quarterly Report”), which are unaudited, include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The results of operations for the interim period are not necessarily indicative of the results to be expected for any other interim period or for the entire fiscal year or for any future period.

The unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). Please refer to the Company’s audited consolidated financial statements and the related notes for the fiscal year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on February 16, 2018 (“2017 Annual Report”).

The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. Actual results could differ from those estimates under different assumptions or conditions.

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606).” The FASB also issued a series of other ASUs, which update ASU 2014-09 (collectively, the “new revenue recognition standard”). This new standard replaces all previous U.S. GAAP guidance on this topic and eliminates all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company adopted this standard effective January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Revenue from substantially all of our contracts with customers continues to be recognized over time as services are rendered. The Company recognized the cumulative effect of adopting this guidance as an adjustment to its opening balance of retained earnings of $2,089, net of tax, primarily related to capitalization of contract costs. Prior period amounts are not retrospectively adjusted and continue to be reported in accordance with the accounting standards in effect for those periods. The impact of the adoption of the new standard was not material to the Company’s condensed consolidated financial statements for the three and nine months ended September 30, 2018. The Company expects the impact to be immaterial on an ongoing basis. See additional information regarding revenue recognition and disaggregated revenue in Note (3), “Revenue Recognition” and Note (5), “Segment Information,” respectively.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities.” The FASB also subsequently issued ASU 2018-03, which provides amendments to ASU 2016-01. These standards require equity investments, except those accounted for using the equity method of accounting, to be measured at fair value with changes in fair value recognized through net income. The new guidance also provides a measurement alternative for equity investments that do not have readily determinable fair values, which were previously accounted for under the cost method of accounting, to be recorded at cost, less impairment, adjusted for observable price changes from orderly transactions for identical or similar investments of the same issuer. For public entities, these standards are effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the standards prospectively effective January 1, 2018 and elected to use the measurement alternative. See additional information in Note (7), “Fair Value Measurement.”

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The standard provides guidance on how certain cash receipts and payments are presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods, and requires a retrospective approach. The Company adopted this standard effective January 1, 2018 and the adoption did not have a material effect on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash.” The standard requires that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents (collectively, “restricted cash”). Therefore, restricted cash should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new guidance is effective for interim and annual periods beginning after December 15, 2017. The Company adopted this standard retrospectively effective January 1, 2018 and included certain restricted cash amounts for the period ended September 30, 2017 within the accompanying condensed consolidated statements of cash flows. These adjustments had no effect on previously reported results of operations or retained earnings. The following table provides a summary of the adjustments from amounts previously reported.

	Nine Months Ended September 30, 2017
	As Previously Reported			Adjustments			As Adjusted
Cash flows from operating activities:
Changes in assets and liabilities:
Other current assets	10,155			(4,055		)	6,100
Restricted cash, cash equivalents and investments balance	(9,761		)	9,769			8
Net cash provided by operating activities	96,382			5,714			102,096
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance	601			(601		)	—
Net cash used in investing activities	(23,444		)	(601		)	(24,045		)
Net increase in cash, cash equivalents and restricted cash	$	9,003		$	5,113		$	14,116
Cash, cash equivalents and restricted cash at the beginning of period	10,622			40,406			51,028
Cash, cash equivalents and restricted cash at the end of period	$	19,625		$	45,519		$	65,144

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets and related notes to the amounts presented in the accompanying condensed consolidated statements of cash flows.

	September 30, 2018			December 31, 2017
Cash and cash equivalents	$	18,614		$	15,147
Restricted cash and cash equivalents (included in other current assets)	22,227			25,506
Restricted cash, cash equivalents and investments	59,453			64,315
Total cash, cash equivalents and restricted cash and investments	100,294			104,968
Less restricted investments	(23,023		)	(6,074		)
Total cash, cash equivalents and restricted cash	$	77,271		$	98,894

There were no other material impacts to the Company's consolidated financial statements as a result of adopting these updated standards.

Reclassification

To conform to the current year presentation, certain reclassifications that are not material have been made to the prior year's balances in Note (10), “Balance Sheet Details."

XML

Acquisitions

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

ACQUISITIONS

As set forth below, the Company completed two acquisitions during the nine months ended September 30, 2018. The Company accounted for each acquisition using the acquisition method of accounting. Accordingly, it recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For each acquisition, the Company did not incur any material acquisition-related costs.

MedPartners Acquisition

On April 9, 2018, the Company completed its acquisition of MedPartners HIM (“MedPartners”), which provides case management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. The initial purchase price of $200,711 included (1) $196,533 cash consideration paid upon acquisition, funded through borrowings under the Company’s $400,000 secured revolving credit facility (the “Senior Credit Facility”), provided for under a credit agreement (the “New Credit Agreement”), dated as of February 9, 2018, by and among the Company and several lenders, and (2) a contingent earn-out payment of up to $20,000 with an estimated fair value of $4,400 as of the acquisition date. The contingent earn-out payment is based on (A) up to $10,000 based on the operating results of MedPartners for the twelve months ending December 31, 2018, and (B) up to $10,000 based on the operating results of MedPartners for the six months ending June 30, 2019. As the acquisition’s operations are not considered material, pro forma information is not provided. The results of MedPartners have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2018, $222 was returned to the Company for the final working capital settlement.

The preliminary allocation of the $200,711 purchase price consisted of (1) $28,425 of fair value of tangible assets acquired, which included $8,403 cash received, (2) $11,809 of liabilities assumed, (3) $103,000 of identified intangible assets, and (4) $81,095 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets includes $46,000 of trademarks and $57,000 of customer relationships with a weighted average useful life of approximately sixteen years.

Phillips DiPisa and Leaders For Today Acquisition

On April 6, 2018, the Company completed its acquisition of two related entities, Phillips DiPisa and Leaders For Today (“PDA and LFT”), which offer a range of leadership staffing and permanent placement solutions for the healthcare industry. The initial purchase price of $35,503 included (1) $30,268 cash consideration paid upon acquisition, funded through cash on hand, and (2) a contingent earn-out payment of up to $7,000 with an estimated fair value of $5,700 as of the acquisition date. The contingent earn-out payment is based on the operating results of PDA and LFT for the twelve months ending December 31, 2018. As the acquisition’s operations are not considered material, pro forma information is not provided. The results of PDA and LFT have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2018, $465 was returned to the Company for the final working capital settlement.

The preliminary allocation of the $35,503 purchase price consisted of (1) $4,356 of fair value of tangible assets acquired, which included $351 cash received, (2) $4,571 of liabilities assumed, (3) $19,110 of identified intangible assets, and (4) $16,608 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets includes $5,400 of trademarks, $8,000 of customer relationships and $5,710 of staffing databases with a weighted average useful life of approximately twelve years.

XML

Revenue Recognition

9 Months Ended

Sep. 30, 2018

Revenue Recognition and Deferred Revenue [Abstract]

Revenue Recognition

REVENUE RECOGNITION

Revenue primarily consists of fees earned from the temporary and permanent placement of healthcare professionals and executives as well as from the Company’s SaaS-based technology, including its vendor management systems and its scheduling software. Revenue is recognized when control of these services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Revenue from temporary staffing services is recognized as the services are rendered by clinical and non-clinical healthcare professionals. Under the Company’s managed services program arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own network of healthcare professionals along with those of third-party subcontractors. Revenue and the related direct costs under MSP arrangements are recorded in accordance with the accounting guidance on reporting revenue gross as a principal versus net as an agent. When the Company uses subcontractors and acts as an agent, revenue is recorded net of the related subcontractor’s expense. Revenue from executive search, physician permanent placement, and recruitment process outsourcing services is recognized as the services are rendered. The Company’s SaaS-based revenue is recognized ratably over the applicable arrangement’s service period.

The Company’s customers are primarily billed as services are rendered. Any fees billed in advance of being earned are recorded as deferred revenue. During the nine months ended September 30, 2018, the amount recognized as revenue that was previously deferred was not material.

Under the new revenue recognition standard, the Company has elected to apply the following practical expedients and optional exemptions:

• Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within selling, general and administrative expenses.

• Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date.

• Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.

See additional information regarding adoption of the new revenue standard in Note (1), “Basis of Presentation” and additional disclosures required by the new revenue standard in Note (5), “Segment Information.”

XML

Net Income Per Common Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

NET INCOME PER COMMON SHARE

NET INCOME PER COMMON SHARE

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period. The following table sets forth the computation of basic and diluted net income per common share for the three and nine months ended September 30, 2018 and 2017, respectively:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Net income	$	27,918	$	28,128	$	106,128	$	91,391
Net income per common share - basic	$	0.59	$	0.59	$	2.23	$	1.91
Net income per common share - diluted	$	0.58	$	0.57	$	2.17	$	1.85
Weighted average common shares outstanding - basic	47,286		47,912		47,556		47,870
Plus dilutive effect of potential common shares	1,243		1,533		1,303		1,610
Weighted average common shares outstanding - diluted	48,529		49,445		48,859		49,480

Share-based awards to purchase 36 and 27 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2018, respectively, because the effect of these instruments was anti-dilutive. Share-based awards to purchase 10 and 14 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2017, respectively, because the effect of these instruments was anti-dilutive.

XML

Segment Information

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

The Company has three reportable segments: nurse and allied solutions, locum tenens solutions, and other workforce solutions.

The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Revenue
Nurse and allied solutions	$	306,292	$	302,933	$	977,199	$	917,183
Locum tenens solutions	101,102		111,415		311,516		322,473
Other workforce solutions	119,448		80,058		318,724		239,722
	$	526,842	$	494,406	$	1,607,439	$	1,479,378
Segment operating income
Nurse and allied solutions	$	42,165	$	40,807	$	137,906	$	134,638
Locum tenens solutions	10,992		14,438		34,321		39,028
Other workforce solutions	29,010		19,890		77,437		61,788
	82,167		75,135		249,664		235,454
Unallocated corporate overhead	26,427		13,698		59,271		44,732
Depreciation and amortization	11,296		8,132		29,788		23,759
Share-based compensation	1,809		2,477		7,954		7,720
Interest expense, net, and other	4,649		4,837		16,360		14,895
Income before income taxes	$	37,986	$	45,991	$	136,291	$	144,348

The Company offers a comprehensive managed services program, in which the Company manages all or a portion of a client's contingent staffing needs. This service includes both the placement of the Company's own healthcare professionals and the utilization of other staffing agencies to fulfill the client's staffing needs. See additional information in Note (3), “Revenue Recognition.” For the three months ended September 30, 2018 and 2017, revenue under the Company’s managed services program arrangements comprised approximately 61% and 59% for nurse and allied solutions revenue, 17% and 13% for locum tenens solutions revenue and 5% and 7% for other workforce solutions revenue, respectively. For the nine months ended September 30, 2018 and 2017, revenue under the Company’s managed services program arrangements comprised approximately 60% and 57% for nurse and allied solutions revenue, 16% and 12% for locum tenens solutions revenue and 7% and 7% for other workforce solutions revenue, respectively.

The following table summarizes the activity related to the carrying value of goodwill by reportable segment:

	Nurse and Allied Solutions		Locum Tenens Solutions		Other Workforce Solutions		Total
Balance, January 1, 2018	$	103,107	$	19,743	$	217,746	$	340,596
Goodwill from MedPartners acquisition	—		—		81,095		81,095
Goodwill from PDA and LFT acquisition	—		—		16,608		16,608
Balance, September 30, 2018	$	103,107	$	19,743	$	315,449	$	438,299
Accumulated impairment loss as of December 31, 2017 and September 30, 2018	$	154,444	$	53,940	$	6,555	$	214,939

XML

New Credit Agreement

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

New Credit Agreement

NEW CREDIT AGREEMENT

On February 9, 2018, the Company entered into the New Credit Agreement with several lenders to provide for the $400,000 Senior Credit Facility to replace its then-existing credit facilities. The Senior Credit Facility includes a $50,000 sublimit for the issuance of letters of credit and a $50,000 sublimit for swingline loans. The obligations of the Company under the New Credit Agreement and the Senior Credit Facility are secured by substantially all of the assets of the Company. Borrowings under the Senior Credit Facility bear interest at floating rates, at the Company’s option, based upon either LIBOR plus a spread of 1.00% to 2.00% or a base rate plus a spread of 0.00% to 1.00%. The applicable spread is determined quarterly based upon the Company’s consolidated net leverage ratio. The Senior Credit Facility is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The maturity date of the Senior Credit Facility is February 9, 2023.

In connection with obtaining the New Credit Agreement, the Company incurred $2,331 in fees paid to lenders and other third parties, which were capitalized and are amortized to interest expense over the term of the New Credit Facility. In addition, the Company wrote off $574 of unamortized financing fees during the nine months ended September 30, 2018 relating to the prior credit facilities.

XML

Fair Value Measurement

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT

The Company’s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note 4—Fair Value Measurement” of the 2017 Annual Report. The Company has not changed the valuation techniques or inputs it uses for its fair value measurement, except for its adoption of ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities," during the nine months ended September 30, 2018. See additional information regarding adoption of the new standard in Note (1), “Basis of Presentation” and additional disclosures below.

Assets and Liabilities Measured on a Recurring Basis

The Company’s restricted cash equivalents that serve as collateral for the Company’s outstanding letters of credit

typically consist of money market funds that are measured at fair value based on quoted prices, which are Level 1 inputs.

The Company’s restricted cash equivalents and investments that serve as collateral for the Company’s captive insurance company primarily consist of commercial paper that is measured at observable market prices for identical securities that are traded in less active markets, which are Level 2 inputs. Of the $61,567 commercial paper issued and outstanding as of September 30, 2018, $23,023 had original maturities greater than three months, which were considered available-for-sale securities. As of December 31, 2017, the Company had $28,708 commercial paper issued and outstanding, of which $6,074 had original maturities greater than three months and were considered available-for-sale securities. The increase in commercial paper issued and outstanding is due to additional restricted investments related to the captive insurance company.

The Company’s contingent consideration liabilities are measured at fair value using a probability-weighted discounted cash flow analysis or a simulation-based methodology for the acquired companies, which are Level 3 inputs. The Company recognizes changes to the fair value of its contingent consideration liabilities in selling, general and administrative expenses in the condensed consolidated statements of comprehensive income.

The following tables present information about the above-referenced assets and liabilities and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:

	Fair Value Measurements as of September 30, 2018
	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	2,739		$	2,739	$	—	$	—
Commercial paper	61,567			—		61,567		—
Acquisition contingent consideration liabilities	(8,793		)	—		—		(8,793		)

	Fair Value Measurements as of December 31, 2017
	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	2,713		$	2,713	$	—	$	—
Commercial paper	28,708			—		28,708		—
Acquisition contingent consideration liabilities	(2,070		)	—		—		(2,070		)

Level 3 Information

The following tables set forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:

	Three Months Ended September 30,
	2018			2017
Balance as of July 1,	$	(10,119	)	$	(1,932	)
Change in fair value of contingent consideration liability from HealthSource Global Stafffing (“HSG”) acquisition	—			(20		)
Change in fair value of contingent consideration liability from PDA and LFT acquisition	(1,194		)	—
Change in fair value of contingent consideration liability from MedPartners acquisition	2,520			—
Balance as of September 30,	$	(8,793	)	$	(1,952	)

	Nine Months Ended September 30,
	2018			2017
Balance as of January 1,	$	(2,070	)	$	(6,816	)
Settlement of The First String Healthcare contingent consideration liability for year ended December 31, 2016	—			3,000
Settlement of HSG contingent consideration liability for year ended December 31, 2016	70			1,930
Settlement of HSG contingent consideration liability for year ended December 31, 2017	2,000			—
Contingent consideration liability from PDA and LFT acquisition on April 6, 2018	(5,700		)	—
Contingent consideration liability from MedPartners acquisition on April 9, 2018	(4,400		)	—
Change in fair value of contingent consideration liability from HSG acquisition	—			(66		)
Change in fair value of contingent consideration liability from PDA and LFT acquisition	(1,213		)	—
Change in fair value of contingent consideration liability from MedPartners acquisition	2,520			—
Balance as of September 30,	$	(8,793	)	$	(1,952	)

Assets Measured on a Non-Recurring Basis

The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to its goodwill, indefinite-lived intangible assets, long-lived assets, and equity investments.

The Company evaluates goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. The Company determines the fair value of its reporting units based on a combination of inputs, including the market capitalization of the Company, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. The Company determines the fair value of its indefinite-lived intangible assets using the income approach (relief-from-royalty method) based on Level 3 inputs.

The Company’s equity investment represents an investment in a non-controlled corporation without a readily determinable market value. The Company has elected to measure the investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes. The fair value is determined by using quoted prices for identical or similar investments of the same issuer, which are Level 2 inputs. The Company recognizes changes to the fair value of its equity investment in interest expense, net, and other in the condensed consolidated statements of comprehensive income.

The following tables set forth a reconciliation of changes in the balance of the equity investment classified as Level 2 in the fair value hierarchy:

	Three Months Ended September 30,
	2018		2017
Balance as of July 1,	$	2,000	$	2,000
Additional investment	4,600		—
Change in fair value	1,359		—
Balance as of September 30,	$	7,959	$	2,000

	Nine Months Ended September 30,
	2018		2017
Balance as of January 1,	$	2,000	$	—
Initial investment	—		2,000
Additional investment	4,600		—
Change in fair value	1,359		—
Balance as of September 30,	$	7,959	$	2,000

There were no triggering events identified, no indication of impairment of the Company’s goodwill, indefinite-lived intangible assets, long-lived assets, or equity investments, and no impairment charges recorded during the nine months ended September 30, 2018 and 2017.

Fair Value of Financial Instruments

The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2018, the Company's senior notes have a carrying amount of $325,000 and an estimated fair value of $314,438. As of December 31, 2017, the senior notes had a carrying amount of $325,000 and an estimated fair value of $335,156. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value. The senior notes were issued in October 2016 and have a fixed rate of 5.125%. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2017 Annual Report.

The fair value of the Company’s long-term self-insurance accruals cannot be estimated as the Company cannot reasonably determine the timing of future payments.

XML

Income Taxes

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of September 30, 2018, the Company is no longer subject to state, local or foreign examinations by tax authorities for tax years before 2009, and the Company is no longer subject to U.S. federal income or payroll tax examinations for tax years before 2015. The IRS conducted, completed, and settled audits of the Company’s 2011-2012 and 2013 tax years related to income and employment tax issues for the Company’s treatment of certain non-taxable per diem allowances and travel benefits in November 2017 and May 2018, respectively.

The Company believes its reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years. Notwithstanding the foregoing, the Company could adjust its provision for income taxes and contingent tax liability based on future developments.

Immaterial Tax Correction Related to Prior Periods

During the first quarter of 2018, the Company identified an error related to the income tax treatment of fair value changes in the cash surrender value of its Company Owned Life Insurance (COLI) for prior years. These fair value changes had not previously been included as a net tax benefit in the provision for prior periods. In accordance with ASC 250, Accounting Changes and Error Corrections, management evaluated the materiality of the error from qualitative and quantitative perspectives, and concluded that the error was not material to the consolidated financial statements of prior years, nor is it believed to be material to 2018’s full year consolidated financial statements. As a result, the Company recorded a net tax benefit of $2,501 in the first quarter of 2018 to adjust for this immaterial error correction.

Tax Cuts and Jobs Act

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate from 35% to 21%.

The Tax Act changes that affected the Company in 2017 are primarily tax rate changes on certain deferred tax assets (“DTAs”) and deferred tax liabilities (“DTLs”). The staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.

The Tax Act also establishes new tax laws that will affect 2018 and beyond, including, but not limited to, (1) reduction of the U.S. federal corporate tax rate; (2) the repeal of the domestic production activity deduction; (3) limitations on the deductibility of certain executive compensation; and (4) limitations on various entertainment and meals deductions.

The Company's accounting for the Tax Act is incomplete, primarily relating to executive compensation. However, the Company was able to make reasonable estimates of these elements and, therefore, recorded provisional adjustments for these items. Final adjustments will be made in the quarter ended December 31, 2018 and are not expected to be material.

XML

Commitments and Contingencies: Legal Proceedings

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES: LEGAL PROCEEDINGS

COMMITMENTS AND CONTINGENCIES: LEGAL PROCEEDINGS

From time to time, the Company is involved in various lawsuits, claims, investigations, and proceedings that arise in the ordinary course of business. These matters typically relate to professional liability, tax, compensation, contract, competitor disputes and employee-related matters and include individual and class action lawsuits, as well as inquiries and investigations by governmental agencies regarding the Company’s employment and compensation practices. Additionally, some of the Company’s clients may also become subject to claims, governmental inquiries and investigations, and legal actions relating to services provided by the Company’s healthcare professionals. Depending upon the particular facts and circumstances, the Company may also be subject to indemnification obligations under its contracts with such clients relating to these matters. The Company records a liability when management believes an adverse outcome from a loss contingency is both probable and the amount, or a range, can be reasonably estimated. Significant judgment is required to determine both probability of loss and the estimated amount. The Company reviews its loss contingencies at least quarterly and adjusts its accruals and/or disclosures to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, or other new information, as deemed necessary. The most significant matters for which the Company has established loss contingencies are class actions related to wage and hour claims under California and Federal law. Specifically, among other claims in these lawsuits, it is alleged that employees were not afforded required breaks or compensated for all time worked, employees' wage statements are not sufficiently clear, and certain expense reimbursements should be included in the regular rate of pay for purposes of calculating overtime rates. The Company believes that its wage and hour practices conform with law in all material respects, but litigation is always subject to inherent uncertainty. As a result, the Company entered into settlement agreements relating to claims in two wage and hour class actions during September and October 2018. The settlement agreements are subject to court approval, which is considered probable. The Company recorded increases to its accruals established in connection with these matters amounting to $12,140 during the three months ended September 30, 2018.

With regard to outstanding loss contingencies as of September 30, 2018, which are included in accounts payable and accrued expenses in the condensed consolidated balance sheet, the Company believes that such matters will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.

XML

Balance Sheet Details

9 Months Ended

Sep. 30, 2018

Balance Sheet Related Disclosures [Abstract]

BALANCE SHEET DETAILS

BALANCE SHEET DETAILS

The consolidated balance sheets detail is as follows as of September 30, 2018 and December 31, 2017:

	September 30, 2018			December 31, 2017
Other current assets:
Restricted cash and cash equivalents	$	22,227		$	25,506
Income tax receivable	2,901			15,898
Other	10,230			9,589
Other current assets	$	35,358		$	50,993
Fixed assets:
Furniture and equipment	$	32,814		$	29,494
Software	155,534			132,770
Leasehold improvements	8,315			9,056
	196,663			171,320
Accumulated depreciation	(109,846		)	(97,889		)
Fixed assets, net	$	86,817		$	73,431
Other assets:
Life insurance cash surrender value	$	58,576		$	48,145
Other	34,630			26,221
Other assets	$	93,206		$	74,366
Accounts payable and accrued expenses:
Trade accounts payable	$	21,217		$	31,420
Subcontractor payable	46,276			41,786
Accrued expenses	37,802			29,238
Loss contingencies	25,042			12,548
Professional liability reserve	8,510			7,672
Other	3,696			7,655
Accounts payable and accrued expenses	$	142,543		$	130,319
Accrued compensation and benefits:
Accrued payroll	$	39,665		$	33,923
Accrued bonuses	18,795			19,489
Accrued travel expense	3,618			3,256
Health insurance reserve	3,820			3,658
Workers compensation reserve	7,789			8,553
Deferred compensation	59,502			49,330
Other	2,443			3,214
Accrued compensation and benefits	$	135,632		$	121,423
Other long-term liabilities:
Workers compensation reserve	$	19,387		$	19,074
Professional liability reserve	37,847			38,964
Deferred rent	15,053			14,744
Unrecognized tax benefits	4,221			5,270
Deferred revenue	994			960
Other	25			267
Other long-term liabilities	$	77,527		$	79,279

XML

Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. Actual results could differ from those estimates under different assumptions or conditions.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606).” The FASB also issued a series of other ASUs, which update ASU 2014-09 (collectively, the “new revenue recognition standard”). This new standard replaces all previous U.S. GAAP guidance on this topic and eliminates all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company adopted this standard effective January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Revenue from substantially all of our contracts with customers continues to be recognized over time as services are rendered. The Company recognized the cumulative effect of adopting this guidance as an adjustment to its opening balance of retained earnings of $2,089, net of tax, primarily related to capitalization of contract costs. Prior period amounts are not retrospectively adjusted and continue to be reported in accordance with the accounting standards in effect for those periods. The impact of the adoption of the new standard was not material to the Company’s condensed consolidated financial statements for the three and nine months ended September 30, 2018. The Company expects the impact to be immaterial on an ongoing basis. See additional information regarding revenue recognition and disaggregated revenue in Note (3), “Revenue Recognition” and Note (5), “Segment Information,” respectively.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities.” The FASB also subsequently issued ASU 2018-03, which provides amendments to ASU 2016-01. These standards require equity investments, except those accounted for using the equity method of accounting, to be measured at fair value with changes in fair value recognized through net income. The new guidance also provides a measurement alternative for equity investments that do not have readily determinable fair values, which were previously accounted for under the cost method of accounting, to be recorded at cost, less impairment, adjusted for observable price changes from orderly transactions for identical or similar investments of the same issuer. For public entities, these standards are effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the standards prospectively effective January 1, 2018 and elected to use the measurement alternative. See additional information in Note (7), “Fair Value Measurement.”

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The standard provides guidance on how certain cash receipts and payments are presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods, and requires a retrospective approach. The Company adopted this standard effective January 1, 2018 and the adoption did not have a material effect on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash.” The standard requires that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents (collectively, “restricted cash”). Therefore, restricted cash should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new guidance is effective for interim and annual periods beginning after December 15, 2017. The Company adopted this standard retrospectively effective January 1, 2018 and included certain restricted cash amounts for the period ended September 30, 2017 within the accompanying condensed consolidated statements of cash flows. These adjustments had no effect on previously reported results of operations or retained earnings. The following table provides a summary of the adjustments from amounts previously reported.

	Nine Months Ended September 30, 2017
	As Previously Reported			Adjustments			As Adjusted
Cash flows from operating activities:
Changes in assets and liabilities:
Other current assets	10,155			(4,055		)	6,100
Restricted cash, cash equivalents and investments balance	(9,761		)	9,769			8
Net cash provided by operating activities	96,382			5,714			102,096
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance	601			(601		)	—
Net cash used in investing activities	(23,444		)	(601		)	(24,045		)
Net increase in cash, cash equivalents and restricted cash	$	9,003		$	5,113		$	14,116
Cash, cash equivalents and restricted cash at the beginning of period	10,622			40,406			51,028
Cash, cash equivalents and restricted cash at the end of period	$	19,625		$	45,519		$	65,144

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets and related notes to the amounts presented in the accompanying condensed consolidated statements of cash flows.

	September 30, 2018			December 31, 2017
Cash and cash equivalents	$	18,614		$	15,147
Restricted cash and cash equivalents (included in other current assets)	22,227			25,506
Restricted cash, cash equivalents and investments	59,453			64,315
Total cash, cash equivalents and restricted cash and investments	100,294			104,968
Less restricted investments	(23,023		)	(6,074		)
Total cash, cash equivalents and restricted cash	$	77,271		$	98,894

There were no other material impacts to the Company's consolidated financial statements as a result of adopting these updated standards.

Revenue Recognition

Revenue primarily consists of fees earned from the temporary and permanent placement of healthcare professionals and executives as well as from the Company’s SaaS-based technology, including its vendor management systems and its scheduling software. Revenue is recognized when control of these services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Revenue from temporary staffing services is recognized as the services are rendered by clinical and non-clinical healthcare professionals. Under the Company’s managed services program arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own network of healthcare professionals along with those of third-party subcontractors. Revenue and the related direct costs under MSP arrangements are recorded in accordance with the accounting guidance on reporting revenue gross as a principal versus net as an agent. When the Company uses subcontractors and acts as an agent, revenue is recorded net of the related subcontractor’s expense. Revenue from executive search, physician permanent placement, and recruitment process outsourcing services is recognized as the services are rendered. The Company’s SaaS-based revenue is recognized ratably over the applicable arrangement’s service period.

The Company’s customers are primarily billed as services are rendered. Any fees billed in advance of being earned are recorded as deferred revenue. During the nine months ended September 30, 2018, the amount recognized as revenue that was previously deferred was not material.

Under the new revenue recognition standard, the Company has elected to apply the following practical expedients and optional exemptions:

• Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within selling, general and administrative expenses.

• Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date.

• Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.

Net Income per Common Share

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.

Segment Information

The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

Fair Value of Financial Instruments

Assets Measured on a Non-Recurring Basis

The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to its goodwill, indefinite-lived intangible assets, long-lived assets, and equity investments.

The Company evaluates goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. The Company determines the fair value of its reporting units based on a combination of inputs, including the market capitalization of the Company, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. The Company determines the fair value of its indefinite-lived intangible assets using the income approach (relief-from-royalty method) based on Level 3 inputs.

Assets and Liabilities Measured on a Recurring Basis

The Company’s restricted cash equivalents that serve as collateral for the Company’s outstanding letters of credit

typically consist of money market funds that are measured at fair value based on quoted prices, which are Level 1 inputs.

The Company’s restricted cash equivalents and investments that serve as collateral for the Company’s captive insurance company primarily consist of commercial paper that is measured at observable market prices for identical securities that are traded in less active markets, which are Level 2 inputs. Of the $61,567 commercial paper issued and outstanding as of September 30, 2018, $23,023 had original maturities greater than three months, which were considered available-for-sale securities. As of December 31, 2017, the Company had $28,708 commercial paper issued and outstanding, of which $6,074 had original maturities greater than three months and were considered available-for-sale securities. The increase in commercial paper issued and outstanding is due to additional restricted investments related to the captive insurance company.

Fair Value of Financial Instruments

The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2018, the Company's senior notes have a carrying amount of $325,000 and an estimated fair value of $314,438. As of December 31, 2017, the senior notes had a carrying amount of $325,000 and an estimated fair value of $335,156. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value. The senior notes were issued in October 2016 and have a fixed rate of 5.125%. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2017 Annual Report.

The fair value of the Company’s long-term self-insurance accruals cannot be estimated as the Company cannot reasonably determine the timing of future payments.

XML

Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

These adjustments had no effect on previously reported results of operations or retained earnings. The following table provides a summary of the adjustments from amounts previously reported.

	Nine Months Ended September 30, 2017
	As Previously Reported			Adjustments			As Adjusted
Cash flows from operating activities:
Changes in assets and liabilities:
Other current assets	10,155			(4,055		)	6,100
Restricted cash, cash equivalents and investments balance	(9,761		)	9,769			8
Net cash provided by operating activities	96,382			5,714			102,096
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance	601			(601		)	—
Net cash used in investing activities	(23,444		)	(601		)	(24,045		)
Net increase in cash, cash equivalents and restricted cash	$	9,003		$	5,113		$	14,116
Cash, cash equivalents and restricted cash at the beginning of period	10,622			40,406			51,028
Cash, cash equivalents and restricted cash at the end of period	$	19,625		$	45,519		$	65,144

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets and related notes to the amounts presented in the accompanying condensed consolidated statements of cash flows.

	September 30, 2018			December 31, 2017
Cash and cash equivalents	$	18,614		$	15,147
Restricted cash and cash equivalents (included in other current assets)	22,227			25,506
Restricted cash, cash equivalents and investments	59,453			64,315
Total cash, cash equivalents and restricted cash and investments	100,294			104,968
Less restricted investments	(23,023		)	(6,074		)
Total cash, cash equivalents and restricted cash	$	77,271		$	98,894

XML

Net Income Per Common Share (Tables)

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Computation of basic and diluted net income per common share

The following table sets forth the computation of basic and diluted net income per common share for the three and nine months ended September 30, 2018 and 2017, respectively:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Net income	$	27,918	$	28,128	$	106,128	$	91,391
Net income per common share - basic	$	0.59	$	0.59	$	2.23	$	1.91
Net income per common share - diluted	$	0.58	$	0.57	$	2.17	$	1.85
Weighted average common shares outstanding - basic	47,286		47,912		47,556		47,870
Plus dilutive effect of potential common shares	1,243		1,533		1,303		1,610
Weighted average common shares outstanding - diluted	48,529		49,445		48,859		49,480

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results

The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Revenue
Nurse and allied solutions	$	306,292	$	302,933	$	977,199	$	917,183
Locum tenens solutions	101,102		111,415		311,516		322,473
Other workforce solutions	119,448		80,058		318,724		239,722
	$	526,842	$	494,406	$	1,607,439	$	1,479,378
Segment operating income
Nurse and allied solutions	$	42,165	$	40,807	$	137,906	$	134,638
Locum tenens solutions	10,992		14,438		34,321		39,028
Other workforce solutions	29,010		19,890		77,437		61,788
	82,167		75,135		249,664		235,454
Unallocated corporate overhead	26,427		13,698		59,271		44,732
Depreciation and amortization	11,296		8,132		29,788		23,759
Share-based compensation	1,809		2,477		7,954		7,720
Interest expense, net, and other	4,649		4,837		16,360		14,895
Income before income taxes	$	37,986	$	45,991	$	136,291	$	144,348

Summary of goodwill by reportable segment

The following table summarizes the activity related to the carrying value of goodwill by reportable segment:

	Nurse and Allied Solutions		Locum Tenens Solutions		Other Workforce Solutions		Total
Balance, January 1, 2018	$	103,107	$	19,743	$	217,746	$	340,596
Goodwill from MedPartners acquisition	—		—		81,095		81,095
Goodwill from PDA and LFT acquisition	—		—		16,608		16,608
Balance, September 30, 2018	$	103,107	$	19,743	$	315,449	$	438,299
Accumulated impairment loss as of December 31, 2017 and September 30, 2018	$	154,444	$	53,940	$	6,555	$	214,939

XML

Fair Value Measurement (Tables)

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of financial assets and liabilities measured at fair value on recurring basis

The following tables present information about the above-referenced assets and liabilities and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:

	Fair Value Measurements as of September 30, 2018
	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	2,739		$	2,739	$	—	$	—
Commercial paper	61,567			—		61,567		—
Acquisition contingent consideration liabilities	(8,793		)	—		—		(8,793		)

	Fair Value Measurements as of December 31, 2017
	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	2,713		$	2,713	$	—	$	—
Commercial paper	28,708			—		28,708		—
Acquisition contingent consideration liabilities	(2,070		)	—		—		(2,070		)

Reconciliations of changes in the fair value of contingent consideration liabilities

The following tables set forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:

	Three Months Ended September 30,
	2018			2017
Balance as of July 1,	$	(10,119	)	$	(1,932	)
Change in fair value of contingent consideration liability from HealthSource Global Stafffing (“HSG”) acquisition	—			(20		)
Change in fair value of contingent consideration liability from PDA and LFT acquisition	(1,194		)	—
Change in fair value of contingent consideration liability from MedPartners acquisition	2,520			—
Balance as of September 30,	$	(8,793	)	$	(1,952	)

Reconciliations of equity investments included in net income

The following tables set forth a reconciliation of changes in the balance of the equity investment classified as Level 2 in the fair value hierarchy:

	Three Months Ended September 30,
	2018		2017
Balance as of July 1,	$	2,000	$	2,000
Additional investment	4,600		—
Change in fair value	1,359		—
Balance as of September 30,	$	7,959	$	2,000

	Nine Months Ended September 30,
	2018		2017
Balance as of January 1,	$	2,000	$	—
Initial investment	—		2,000
Additional investment	4,600		—
Change in fair value	1,359		—
Balance as of September 30,	$	7,959	$	2,000

XML

Balance Sheet Details (Tables)

9 Months Ended

Sep. 30, 2018

Balance Sheet Related Disclosures [Abstract]

Schedule of Supplemental Balance Sheet Disclosures

The consolidated balance sheets detail is as follows as of September 30, 2018 and December 31, 2017:

	September 30, 2018			December 31, 2017
Other current assets:
Restricted cash and cash equivalents	$	22,227		$	25,506
Income tax receivable	2,901			15,898
Other	10,230			9,589
Other current assets	$	35,358		$	50,993
Fixed assets:
Furniture and equipment	$	32,814		$	29,494
Software	155,534			132,770
Leasehold improvements	8,315			9,056
	196,663			171,320
Accumulated depreciation	(109,846		)	(97,889		)
Fixed assets, net	$	86,817		$	73,431
Other assets:
Life insurance cash surrender value	$	58,576		$	48,145
Other	34,630			26,221
Other assets	$	93,206		$	74,366
Accounts payable and accrued expenses:
Trade accounts payable	$	21,217		$	31,420
Subcontractor payable	46,276			41,786
Accrued expenses	37,802			29,238
Loss contingencies	25,042			12,548
Professional liability reserve	8,510			7,672
Other	3,696			7,655
Accounts payable and accrued expenses	$	142,543		$	130,319
Accrued compensation and benefits:
Accrued payroll	$	39,665		$	33,923
Accrued bonuses	18,795			19,489
Accrued travel expense	3,618			3,256
Health insurance reserve	3,820			3,658
Workers compensation reserve	7,789			8,553
Deferred compensation	59,502			49,330
Other	2,443			3,214
Accrued compensation and benefits	$	135,632		$	121,423
Other long-term liabilities:
Workers compensation reserve	$	19,387		$	19,074
Professional liability reserve	37,847			38,964
Deferred rent	15,053			14,744
Unrecognized tax benefits	4,221			5,270
Deferred revenue	994			960
Other	25			267
Other long-term liabilities	$	77,527		$	79,279

XML

Basis of Presentation Basis of Presentation - Recently Adopted Accounting Pronouncements (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017		Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Retained earnings	$ 250,446				$ 142,229
Cash flows from operating activities:
Other current assets	446	$ 6,100	[1]
Restricted cash, cash equivalents and investments balance	(86)	8	[1]
Net cash provided by operating activities	168,046	102,096	[1]
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance		0
Net cash used in investing activities	(271,648)	(24,045)	[1]
Net increase in cash, cash equivalents and restricted cash	(21,623)	14,116	[1]
Cash, cash equivalents and restricted cash at the beginning of period	98,894	51,028	[1]
Cash, cash equivalents and restricted cash at the end of period	77,271	65,144	[1]
Cash and cash equivalents	18,614				15,147
Restricted cash and cash equivalents (included in other current assets)	22,227				25,506
Restricted cash, cash equivalents and investments	59,453				64,315
Total cash, cash equivalents and restricted cash and investments	100,294				104,968
Less restricted investments	$ (23,023)				$ (6,074)
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Retained earnings				$ 2,089
As Previously Reported
Cash flows from operating activities:
Other current assets		10,155
Restricted cash, cash equivalents and investments balance		(9,761)
Net cash provided by operating activities		96,382
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance		601
Net cash used in investing activities		(23,444)
Net increase in cash, cash equivalents and restricted cash		9,003
Cash, cash equivalents and restricted cash at the beginning of period		10,622
Cash, cash equivalents and restricted cash at the end of period		19,625
Adjustments | Accounting Standards Update 2016-18 [Member]
Cash flows from operating activities:
Other current assets		(4,055)
Restricted cash, cash equivalents and investments balance		9,769
Net cash provided by operating activities		5,714
Cash flows from investing activities
Change in restricted cash, cash equivalents and investments balance		(601)
Net cash used in investing activities		(601)
Net increase in cash, cash equivalents and restricted cash		5,113
Cash, cash equivalents and restricted cash at the beginning of period		40,406
Cash, cash equivalents and restricted cash at the end of period		$ 45,519

[1] See Note (1) for a summary of adjustments.

XML

Acquisitions (Details)			3 Months Ended	9 Months Ended
	Apr. 09, 2018 USD ($)	Apr. 06, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2018 USD ($) aquisition	Sep. 30, 2017 USD ($)	[1]	Feb. 09, 2018 USD ($)	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Number of acquisitions | aquisition				2
Proceeds from line of credit				$ 195,000,000	$ 0
Goodwill			$ 438,299,000	$ 438,299,000				$ 340,596,000
MedPartners
Business Acquisition [Line Items]
Initial purchase price	$ 200,711,000
Cash consideration	196,533,000
Tiered contingent earn-out payment	20,000,000
Estimated fair value of contingent earn-out payment	4,400,000
Working capital settlement received			222,000
Tangible assets acquired, including cash received	28,425,000
Cash received	8,403,000
Liabilities assumed	11,809,000
Intangible assets acquired	103,000,000
Goodwill	$ 81,095,000
Intangible assets, weighted-average useful life (in years)	16 years
MedPartners | Based on operating results for the twelve months ending December 31, 2018
Business Acquisition [Line Items]
Tiered contingent earn-out payment	$ 10,000,000
MedPartners | Based on operating results for the six months ending June 30, 2019
Business Acquisition [Line Items]
Tiered contingent earn-out payment	10,000,000
MedPartners | Trademarks
Business Acquisition [Line Items]
Intangible assets acquired	46,000,000
MedPartners | Customer Relationships
Business Acquisition [Line Items]
Intangible assets acquired	$ 57,000,000
PDA and LFT
Business Acquisition [Line Items]
Initial purchase price		$ 35,503,000
Cash consideration		30,268,000
Tiered contingent earn-out payment		7,000,000
Estimated fair value of contingent earn-out payment		5,700,000
Working capital settlement received			$ 465,000
Tangible assets acquired, including cash received		4,356,000
Cash received		351,000
Liabilities assumed		4,571,000
Intangible assets acquired		19,110,000
Goodwill		$ 16,608,000
Intangible assets, weighted-average useful life (in years)		12 years
PDA and LFT | Trademarks
Business Acquisition [Line Items]
Intangible assets acquired		$ 5,400,000
PDA and LFT | Customer Relationships
Business Acquisition [Line Items]
Intangible assets acquired		8,000,000
PDA and LFT | Staffing Databases
Business Acquisition [Line Items]
Intangible assets acquired		$ 5,710,000
Revolving Credit Facility | Line of Credit
Business Acquisition [Line Items]
Maximum borrowing capacity							$ 400,000,000

[1] See Note (1) for a summary of adjustments.

XML

Net Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Computation of basic and diluted net income per common share
Net income	$ 27,918	$ 28,128	$ 106,128	$ 91,391	[1]
Net income per common share - basic (in dollars per share)	$ 0.59	$ 0.59	$ 2.23	$ 1.91
Net income per common share - diluted (in dollars per share)	$ 0.58	$ 0.57	$ 2.17	$ 1.85
Weighted average common shares outstanding - basic (in shares)	47,286	47,912	47,556	47,870
Plus dilutive effect of potential common shares (in shares)	1,243	1,533	1,303	1,610
Weighted average common shares outstanding - diluted (in shares)	48,529	49,445	48,859	49,480
Common stock excluded from calculation of EPS (in shares)	36	10	27	14

[1] See Note (1) for a summary of adjustments.

XML

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) segment	Sep. 30, 2017 USD ($)
Segment Reporting, Revenue Reconciling Item [Line Items]
Number of reportable segments | segment			3
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue	$ 526,842	$ 494,406	$ 1,607,439	$ 1,479,378
Segment operating income	42,635	50,828	152,651	159,243
Depreciation and amortization	11,296	8,132	29,788	23,759	[1]
Share-based compensation	1,809	2,477	7,954	7,720	[1]
Interest expense, net, and other	4,649	4,837	16,360	14,895
Income before income taxes	37,986	45,991	136,291	144,348
Operating segments
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue	526,842	494,406	1,607,439	1,479,378
Segment operating income	82,167	75,135	249,664	235,454
Operating segments | Nurse and Allied Solutions
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue	306,292	302,933	977,199	917,183
Segment operating income	42,165	40,807	137,906	134,638
Operating segments | Locum Tenens Solutions
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue	101,102	111,415	311,516	322,473
Segment operating income	10,992	14,438	34,321	39,028
Operating segments | Other Workforce Solutions
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue	119,448	80,058	318,724	239,722
Segment operating income	29,010	19,890	77,437	61,788
Unallocated corporate overhead
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Unallocated corporate overhead	$ 26,427	$ 13,698	$ 59,271	$ 44,732
Product concentration risk | Sales revenue, net | Managed Services Program Arrangements | Nurse and Allied Solutions
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue from contract with customer, percent	61.00%	59.00%	60.00%	57.00%
Product concentration risk | Sales revenue, net | Managed Services Program Arrangements | Locum Tenens Solutions
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue from contract with customer, percent	17.00%	13.00%	16.00%	12.00%
Product concentration risk | Sales revenue, net | Managed Services Program Arrangements | Other Workforce Solutions
Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results
Revenue from contract with customer, percent	5.00%	7.00%	7.00%	7.00%

[1] See Note (1) for a summary of adjustments.

XML

Segment Information - Goodwill (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 340,596
Goodwill, ending balance	438,299
Accumulated impairment loss	214,939	$ 214,939
Nurse and Allied Solutions
Goodwill [Roll Forward]
Goodwill, beginning balance	103,107
Goodwill, ending balance	103,107
Accumulated impairment loss	154,444	154,444
Locum Tenens Solutions
Goodwill [Roll Forward]
Goodwill, beginning balance	19,743
Goodwill, ending balance	19,743
Accumulated impairment loss	53,940	53,940
Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill, beginning balance	217,746
Goodwill, ending balance	315,449
Accumulated impairment loss	6,555	$ 6,555
MedPartners
Goodwill [Roll Forward]
Goodwill acquired	81,095
MedPartners | Nurse and Allied Solutions
Goodwill [Roll Forward]
Goodwill acquired	0
MedPartners | Locum Tenens Solutions
Goodwill [Roll Forward]
Goodwill acquired	0
MedPartners | Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill acquired	81,095
PDA and LFT
Goodwill [Roll Forward]
Goodwill acquired	16,608
PDA and LFT | Nurse and Allied Solutions
Goodwill [Roll Forward]
Goodwill acquired	0
PDA and LFT | Locum Tenens Solutions
Goodwill [Roll Forward]
Goodwill acquired	0
PDA and LFT | Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill acquired	$ 16,608

XML

New Credit Agreement (Details) - Line of Credit - USD ($)		9 Months Ended
	Feb. 09, 2018	Sep. 30, 2018
Debt Instrument [Line Items]
Fees paid to lenders and other third parties		$ 2,331,000
Unamortized financing fees written off		$ 574,000
Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000,000
Revolving Credit Facility, Swing Line Loan
Debt Instrument [Line Items]
Maximum borrowing capacity	50,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 400,000,000
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.00%
Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%
Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%

XML

Fair Value Measurement - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Oct. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charges	$ 0	$ 0
Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commercial paper	61,567,000		$ 28,708,000
Commercial paper | Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commercial paper	61,567,000		28,708,000
Available for sale securities	23,023,000		6,074,000
5.125% Senior Notes due 2024 [Member] | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount of senior notes	325,000,000		325,000,000
Estimated fair value of senior notes	$ 314,438,000		$ 335,156,000
5.125% Senior Notes Due 2024 | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate				5.125%

XML

Fair Value Measurement - Financial Assets and Liabilities (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Money market funds
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	$ 2,739	$ 2,713
Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	2,739	2,713
Money market funds | Significant Other Observable Inputs (Level 2)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	0	0
Money market funds | Significant Unobservable Inputs (Level 3)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	0	0
Commercial paper
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	61,567	28,708
Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	0	0
Commercial paper | Significant Other Observable Inputs (Level 2)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	61,567	28,708
Commercial paper | Significant Unobservable Inputs (Level 3)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	0	0
Acquisition contingent consideration liabilities
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	(8,793)	(2,070)
Acquisition contingent consideration liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	0	0
Acquisition contingent consideration liabilities | Significant Other Observable Inputs (Level 2)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	0	0
Acquisition contingent consideration liabilities | Significant Unobservable Inputs (Level 3)
Schedule of financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value	$ (8,793)	$ (2,070)

XML

Fair Value Measurement - Reconciliation of Changes in Contingent Consideration Liabilities (Details) - Significant Unobservable Inputs (Level 3) - Acquisition contingent consideration liabilities - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ (10,119)	$ (1,932)	$ (2,070)	$ (6,816)
Ending balance	(8,793)	(1,952)	(8,793)	(1,952)
HSG
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in fair value of contingent consideration earn-out liability from acquisition	0	(20)	0	(66)
PDA and LFT
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration earn-out liability			(5,700)	0
Change in fair value of contingent consideration earn-out liability from acquisition	(1,194)	0	(1,213)	0
MedPartners
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration earn-out liability			(4,400)	0
Change in fair value of contingent consideration earn-out liability from acquisition	$ 2,520	$ 0	2,520	0
TFS
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Settlement of earn-out			0	3,000
2016 Earn-out | HSG
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Settlement of earn-out			70	1,930
2017 Earn-out | HSG
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Settlement of earn-out			$ 2,000	$ 0

XML

Fair Value Measurement - Reconciliation of Equity Investments Included in Net Income (Details) - Fair Value, Measurements, Nonrecurring - Significant Other Observable Inputs (Level 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Equity Securities without a Readily Determinable Fair Value [Roll Forward]
Equity investment, beginning balance	$ 2,000	$ 2,000	$ 2,000	$ 0
Cash investment	4,600	0	4,600	2,000
Change in fair value	1,359	0	1,359	0
Equity investment, ending balance	$ 7,959	$ 2,000	$ 7,959	$ 2,000

XML

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax benefit	$ (10,068)		$ (17,863)	$ (30,163)	$ (52,957)
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax benefit		$ 2,501

XML

Commitments and Contingencies: Legal Proceedings (Details) - Wage and Hour claims - Pending Litigation $ in Thousands	3 Months Ended
	Sep. 30, 2018 USD ($)	Oct. 31, 2018 claim
Loss Contingencies [Line Items]
Increase to loss contingency accruals | $	$ 12,140
Subsequent Event
Loss Contingencies [Line Items]
Number of class actions related to wage and hour claims | claim		2

XML

Balance Sheet Details (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Other current assets:
Restricted cash and cash equivalents	$ 22,227	$ 25,506
Income tax receivable	2,901	15,898
Other	10,230	9,589
Other current assets	35,358	50,993
Fixed assets:
Furniture and equipment	32,814	29,494
Software	155,534	132,770
Leasehold improvements	8,315	9,056
Fixed assets, gross	196,663	171,320
Accumulated depreciation	(109,846)	(97,889)
Fixed assets, net	86,817	73,431
Other assets:
Life insurance cash surrender value	58,576	48,145
Other	34,630	26,221
Other assets	93,206	74,366
Accounts payable and accrued expenses:
Trade accounts payable	21,217	31,420
Subcontractor payable	46,276	41,786
Accrued expenses	37,802	29,238
Loss contingencies	25,042	12,548
Professional liability reserve	8,510	7,672
Other	3,696	7,655
Accounts payable and accrued expenses	142,543	130,319
Accrued compensation and benefits:
Accrued payroll	39,665	33,923
Accrued bonuses	18,795	19,489
Accrued travel expense	3,618	3,256
Health insurance reserve	3,820	3,658
Workers compensation reserve	7,789	8,553
Deferred compensation	59,502	49,330
Other	2,443	3,214
Accrued compensation and benefits	135,632	121,423
Other long-term liabilities:
Workers compensation reserve	19,387	19,074
Professional liability reserve	37,847	38,964
Deferred rent	15,053	14,744
Unrecognized tax benefits	4,221	5,270
Deferred revenue	994	960
Other	25	267
Other long-term liabilities	$ 77,527	$ 79,279